Pattern 10
KIDNEY FUNCTION-ASSOCIATED ONE-CARBON METABOLISM DISRUPTION AND MARKER DISTORTION
How reduced kidney function can alter homocysteine, S-adenosylhomocysteine, methylmalonic acid, cystathionine, dimethylglycine, and the interpretation of methylation-related markers
Kidney Function-Associated One-Carbon Metabolism Disruption and Marker Distortion describes a secondary context in which reduced kidney function can alter both the metabolism and the measured concentrations of compounds connected to the methionine cycle.
The pattern may include elevated homocysteine, S-adenosylhomocysteine (SAH), S-adenosylmethionine (SAM), methylmalonic acid (MMA), cystathionine, dimethylglycine (DMG), and other related metabolites. The mechanisms are not limited to passive retention.
They can also involve reduced metabolic clearance, altered remethylation and transmethylation flux, changes in cofactor handling, dialysis-related nutrient losses, inflammation, nutritional restriction, medication effects, and the broader uremic environment.
This is not a recognized stand-alone diagnosis and should not be interpreted as a primary methylation disorder. Its main value is as an interpretation framework.
Kidney-related changes may resemble folate-limited remethylation, vitamin B12 deficiency, impaired transsulfuration, or reduced methylation potential.
At the same time, genuine nutrient deficiency can coexist with chronic kidney disease (CKD).
The central task is therefore not to assign one explanation to one abnormal marker, but to determine how much of the signal may reflect kidney function, how much may reflect nutrient status or another condition, and whether an intervention changes a number, a biochemical pathway, symptoms, or a clinically important outcome.
The existence of kidney-associated changes in homocysteine, SAH, SAM, MMA, cystathionine, and DMG is supported by human mechanistic studies and observational cohorts. The use of these findings as a unified clinical “methylation diagnosis” is not established.
The pattern may include elevated homocysteine, S-adenosylhomocysteine (SAH), S-adenosylmethionine (SAM), methylmalonic acid (MMA), cystathionine, dimethylglycine (DMG), and other related metabolites. The mechanisms are not limited to passive retention.
They can also involve reduced metabolic clearance, altered remethylation and transmethylation flux, changes in cofactor handling, dialysis-related nutrient losses, inflammation, nutritional restriction, medication effects, and the broader uremic environment.
This is not a recognized stand-alone diagnosis and should not be interpreted as a primary methylation disorder. Its main value is as an interpretation framework.
Kidney-related changes may resemble folate-limited remethylation, vitamin B12 deficiency, impaired transsulfuration, or reduced methylation potential.
At the same time, genuine nutrient deficiency can coexist with chronic kidney disease (CKD).
The central task is therefore not to assign one explanation to one abnormal marker, but to determine how much of the signal may reflect kidney function, how much may reflect nutrient status or another condition, and whether an intervention changes a number, a biochemical pathway, symptoms, or a clinically important outcome.
The existence of kidney-associated changes in homocysteine, SAH, SAM, MMA, cystathionine, and DMG is supported by human mechanistic studies and observational cohorts. The use of these findings as a unified clinical “methylation diagnosis” is not established.
Explore This Pattern
The kidney as a metabolic organ, not only a filtration system.
Homocysteine, methionine, SAM, and SAH.
MMA, cystathionine, DMG, betaine, choline, serine, and glycine.
How kidney function can mimic vitamin deficiency or methylation dysfunction.
Differential interpretation rather than single-marker diagnosis.
Why fatigue, brain fog, neuropathy, and weakness do not identify the mechanism.
Why lowering a marker is not the same as correcting the mechanism.
How to organize kidney function, one-carbon markers, nutrient status, and uncertainty.
Why Kidney Function Matters in One-Carbon Metabolism
The kidney as a metabolic organ, not only a filtration system
The kidney is often introduced as a filtration organ, but filtration is only part of its metabolic role.
Renal tissue takes up, transforms, synthesizes, and releases amino acids and related compounds. It contributes to acid-base balance, ammoniagenesis, gluconeogenesis, arginine synthesis, and the handling of sulfur-containing amino acids.
For homocysteine, the normal kidney appears to contribute through uptake and metabolism rather than through urinary excretion of large amounts of unchanged circulating homocysteine. Most plasma homocysteine is protein-bound, and urinary excretion represents only a small component of total turnover.
Consequently, the inverse relationship between kidney function and plasma homocysteine cannot be reduced to a simple blocked-filter model.
Stable-isotope work in end-stage kidney disease (ESKD) has shown reduced whole-body homocysteine remethylation and reduced methionine transmethylation. Other studies have described impaired metabolic clearance, altered intracellular handling of S-adenosylhomocysteine, and changes in downstream sulfur metabolites.
These findings support a broader model: declining kidney function changes the environment in which one-carbon metabolism operates. The resulting plasma pattern is influenced by the kidney, liver, nutritional state, dialysis modality, inflammation, medications, and the distribution of metabolites between plasma and cells.
Renal tissue takes up, transforms, synthesizes, and releases amino acids and related compounds. It contributes to acid-base balance, ammoniagenesis, gluconeogenesis, arginine synthesis, and the handling of sulfur-containing amino acids.
For homocysteine, the normal kidney appears to contribute through uptake and metabolism rather than through urinary excretion of large amounts of unchanged circulating homocysteine. Most plasma homocysteine is protein-bound, and urinary excretion represents only a small component of total turnover.
Consequently, the inverse relationship between kidney function and plasma homocysteine cannot be reduced to a simple blocked-filter model.
Stable-isotope work in end-stage kidney disease (ESKD) has shown reduced whole-body homocysteine remethylation and reduced methionine transmethylation. Other studies have described impaired metabolic clearance, altered intracellular handling of S-adenosylhomocysteine, and changes in downstream sulfur metabolites.
These findings support a broader model: declining kidney function changes the environment in which one-carbon metabolism operates. The resulting plasma pattern is influenced by the kidney, liver, nutritional state, dialysis modality, inflammation, medications, and the distribution of metabolites between plasma and cells.
Filtration, metabolic clearance, and tissue redistribution are different processes
Glomerular filtration describes movement of filterable substances from plasma into the nephron.
Tubular handling includes reabsorption, secretion, and metabolism within the nephron.
Metabolic clearance describes removal by biochemical conversion, which may occur in the kidney or other tissues.
Distribution effects describe changes in how a compound is bound, transported, or compartmentalized.
A single measured concentration can be affected by all four. This distinction is essential because one-carbon markers do not behave uniformly.
Methylmalonic acid is a relatively small organic acid and is strongly influenced by kidney function, but its concentration also reflects endogenous propionate metabolism and vitamin B12-dependent methylmalonyl-CoA mutase activity.
Homocysteine is largely protein-bound and reflects systemic production and metabolic recycling. S-adenosylhomocysteine is intracellularly produced, is a potent product inhibitor of methyltransferases, and may rise in plasma and cells under uremic conditions.
Dimethylglycine is generated when betaine donates a methyl group to homocysteine through betaine-homocysteine methyltransferase (BHMT). Each marker therefore needs its own mechanistic interpretation.
Tubular handling includes reabsorption, secretion, and metabolism within the nephron.
Metabolic clearance describes removal by biochemical conversion, which may occur in the kidney or other tissues.
Distribution effects describe changes in how a compound is bound, transported, or compartmentalized.
A single measured concentration can be affected by all four. This distinction is essential because one-carbon markers do not behave uniformly.
Methylmalonic acid is a relatively small organic acid and is strongly influenced by kidney function, but its concentration also reflects endogenous propionate metabolism and vitamin B12-dependent methylmalonyl-CoA mutase activity.
Homocysteine is largely protein-bound and reflects systemic production and metabolic recycling. S-adenosylhomocysteine is intracellularly produced, is a potent product inhibitor of methyltransferases, and may rise in plasma and cells under uremic conditions.
Dimethylglycine is generated when betaine donates a methyl group to homocysteine through betaine-homocysteine methyltransferase (BHMT). Each marker therefore needs its own mechanistic interpretation.
CKD is not defined by one creatinine result
Kidney Disease: Improving Global Outcomes (KDIGO) defines chronic kidney disease as abnormalities of kidney structure or function present for at least three months, with implications for health. Classification uses cause, glomerular filtration rate (GFR) category, and albuminuria category. A person may have preserved estimated glomerular filtration rate (eGFR) but persistent albuminuria or another marker of kidney damage. Conversely, an isolated lower eGFR can be transient, analytically distorted, or related to a non-steady state.
For interpreting one-carbon markers, the relevant question is not merely “Does the person have a CKD label?”
It is “What is the best available estimate of filtration and kidney damage at the time these markers were measured?”
Creatinine-based eGFR can be biased by muscle mass, meat intake, creatine use, amputation, cachexia, intense exercise, and some medications.
Cystatin C has different non-GFR determinants, including inflammation, glucocorticoid use, thyroid status, and body composition. KDIGO recommends considering combined creatinine-cystatin C equations when creatinine alone may be inaccurate and when greater precision would affect decisions.
For interpreting one-carbon markers, the relevant question is not merely “Does the person have a CKD label?”
It is “What is the best available estimate of filtration and kidney damage at the time these markers were measured?”
Creatinine-based eGFR can be biased by muscle mass, meat intake, creatine use, amputation, cachexia, intense exercise, and some medications.
Cystatin C has different non-GFR determinants, including inflammation, glucocorticoid use, thyroid status, and body composition. KDIGO recommends considering combined creatinine-cystatin C equations when creatinine alone may be inaccurate and when greater precision would affect decisions.
Renal measure
What it contributes
Common interpretive limitation
Serum creatinine and eGFRcr
Widely available estimate of filtration
Affected by muscle mass, diet, creatine, medications, and non-steady-state conditions.
Cystatin C and eGFRcys
Alternative filtration estimate less dependent on muscle mass
Affected by inflammation, glucocorticoids, thyroid function, adiposity, and assay factors.
Combined eGFRcr-cys
Often improves accuracy when markers disagree
Still an estimate and may not resolve all non-GFR influences.
Urine albumin-to-creatinine ratio
Marker of kidney damage and risk, even with preserved eGFR
Biological variability, exercise, infection, menstruation, and collection conditions.
Measured GFR
More direct assessment when precision is essential
Resource intensive and not routinely required.
Dialysis status and residual kidney function
Defines a distinct metabolic and clearance environment
Dialysis modality, membrane, frequency, nutrition, and residual function differ widely.
The timing and trajectory matter
A one-time eGFR of 58 mL/min/1.73 m² does not have the same meaning as a stable three-year trajectory near 58, an acute fall from 95 to 58, or a creatinine-based estimate of 58 with a cystatin C-based estimate of 82.
Similarly, a homocysteine value should be interpreted alongside the timing of kidney measurements, recent illness, hydration, fasting status, medication changes, and laboratory handling. Red cells continue to release homocysteine after blood collection; delayed plasma separation can increase measured concentrations. Pre-analytical error can therefore add another layer to an already confounded biomarker.
Published clinical example 1: the kidney contribution can dominate the marker
Loikas et al., 2007, 1,011 older adults [17]. Kidney function assessed with cystatin C correlated strongly with plasma total homocysteine and significantly with serum MMA. In that cohort, the authors concluded that homocysteine and MMA were compromised as screening markers for vitamin B12 deficiency when renal impairment was common.
Interpretation: The study does not prove that elevated MMA or homocysteine is meaningless. It demonstrates that renal function can be a major determinant and must be part of the diagnostic model.
Similarly, a homocysteine value should be interpreted alongside the timing of kidney measurements, recent illness, hydration, fasting status, medication changes, and laboratory handling. Red cells continue to release homocysteine after blood collection; delayed plasma separation can increase measured concentrations. Pre-analytical error can therefore add another layer to an already confounded biomarker.
Published clinical example 1: the kidney contribution can dominate the marker
Loikas et al., 2007, 1,011 older adults [17]. Kidney function assessed with cystatin C correlated strongly with plasma total homocysteine and significantly with serum MMA. In that cohort, the authors concluded that homocysteine and MMA were compromised as screening markers for vitamin B12 deficiency when renal impairment was common.
Interpretation: The study does not prove that elevated MMA or homocysteine is meaningless. It demonstrates that renal function can be a major determinant and must be part of the diagnostic model.
Albuminuria and tubular disease add information that eGFR cannot provide
Estimated glomerular filtration rate describes filtration, not every function of the kidney.
Persistent albuminuria may identify kidney damage even when estimated glomerular filtration rate remains in a range that appears reassuring.
Tubulointerstitial disorders can also alter handling of organic acids, amino acids, and vitamins without producing the same pattern as a primarily glomerular disorder.
This matters because most research connecting one-carbon metabolites to kidney disease uses estimated glomerular filtration rate, while fewer studies distinguish glomerular, tubular, and albuminuric phenotypes.
A person with preserved filtration and marked albuminuria therefore cannot be assumed to have the same one-carbon pattern as a person with low filtration and little albuminuria.
The reverse is also important. A mildly reduced estimated glomerular filtration rate without albuminuria may reflect age-related filtration loss, vascular disease, low nephron reserve, medication effects, or a creatinine-related estimation problem.
The one-carbon marker may still be influenced, but the confidence of attribution depends on chronicity and on whether the renal estimate is credible. The pattern should therefore be framed as kidney-function-associated rather than CKD-stage-specific.
Persistent albuminuria may identify kidney damage even when estimated glomerular filtration rate remains in a range that appears reassuring.
Tubulointerstitial disorders can also alter handling of organic acids, amino acids, and vitamins without producing the same pattern as a primarily glomerular disorder.
This matters because most research connecting one-carbon metabolites to kidney disease uses estimated glomerular filtration rate, while fewer studies distinguish glomerular, tubular, and albuminuric phenotypes.
A person with preserved filtration and marked albuminuria therefore cannot be assumed to have the same one-carbon pattern as a person with low filtration and little albuminuria.
The reverse is also important. A mildly reduced estimated glomerular filtration rate without albuminuria may reflect age-related filtration loss, vascular disease, low nephron reserve, medication effects, or a creatinine-related estimation problem.
The one-carbon marker may still be influenced, but the confidence of attribution depends on chronicity and on whether the renal estimate is credible. The pattern should therefore be framed as kidney-function-associated rather than CKD-stage-specific.
Why modest reductions in kidney function may still affect interpretation
The strongest biochemical abnormalities are found in advanced chronic kidney disease and dialysis, but marker distortion does not begin at a single cliff edge.
Population data show graded relationships between kidney function and homocysteine or methylmalonic acid. This does not mean that every estimated glomerular filtration rate of 70 explains every abnormal result.
It means that renal influence is continuous, while clinical categories are discrete. Near a diagnostic threshold, a modest renal effect can be enough to change whether a result is labelled normal or high.
This is especially relevant in older adults, people with low muscle mass, and people whose creatinine-based estimated glomerular filtration rate is reported only as greater than 60 mL/min/1.73 m².
A laboratory report may conceal whether the estimate is 62 or 105. When methylmalonic acid or homocysteine is being used to resolve an uncertain vitamin diagnosis, that lost precision can matter.
A cystatin C-based or combined estimate may sometimes clarify the context, but it should be ordered because greater accuracy would change interpretation, not as an automatic response to every borderline marker.
Population data show graded relationships between kidney function and homocysteine or methylmalonic acid. This does not mean that every estimated glomerular filtration rate of 70 explains every abnormal result.
It means that renal influence is continuous, while clinical categories are discrete. Near a diagnostic threshold, a modest renal effect can be enough to change whether a result is labelled normal or high.
This is especially relevant in older adults, people with low muscle mass, and people whose creatinine-based estimated glomerular filtration rate is reported only as greater than 60 mL/min/1.73 m².
A laboratory report may conceal whether the estimate is 62 or 105. When methylmalonic acid or homocysteine is being used to resolve an uncertain vitamin diagnosis, that lost precision can matter.
A cystatin C-based or combined estimate may sometimes clarify the context, but it should be ordered because greater accuracy would change interpretation, not as an automatic response to every borderline marker.
Acute illness and non-steady-state kidney function
Creatinine-based equations assume a relatively steady creatinine concentration. During acute kidney injury, rapid fluid shifts, severe infection, hospitalization, or recovery from an acute event, serum creatinine may lag behind the true change in filtration.
One-carbon metabolites can also shift because of catabolism, reduced intake, inflammation, medications, transfusion, and altered gut function. A panel obtained in this setting may be biologically real but unsuitable for assigning a stable nutritional or methylation phenotype.
A safer interpretation distinguishes an acute-state question from a chronic-state question. During acute illness the immediate task is to understand the acute renal and medical problem.
After recovery, repeating selected markers under more stable conditions can show which abnormalities persist. This is not merely laboratory housekeeping. It prevents a transient uremic or catabolic signal from being converted into a permanent supplement identity.
One-carbon metabolites can also shift because of catabolism, reduced intake, inflammation, medications, transfusion, and altered gut function. A panel obtained in this setting may be biologically real but unsuitable for assigning a stable nutritional or methylation phenotype.
A safer interpretation distinguishes an acute-state question from a chronic-state question. During acute illness the immediate task is to understand the acute renal and medical problem.
After recovery, repeating selected markers under more stable conditions can show which abnormalities persist. This is not merely laboratory housekeeping. It prevents a transient uremic or catabolic signal from being converted into a permanent supplement identity.
Dialysis creates a distinct metabolic setting
Dialysis is not simply an extremely low estimated glomerular filtration rate. Hemodialysis and peritoneal dialysis differ in solute removal, treatment frequency, membrane exposure, protein and amino-acid losses, residual kidney function, dietary restrictions, inflammation, and medication use.
The timing of blood sampling relative to a dialysis session can influence concentrations. A pre-dialysis value, an immediate post-dialysis value, and an interdialytic value do not answer the same question.
Residual kidney function also varies widely among dialysis patients and can contribute meaningfully to clearance. Two people receiving the same nominal dialysis schedule may therefore have different metabolite profiles. For educational interpretation, “on dialysis” is a starting context, not a complete explanation.
The timing of blood sampling relative to a dialysis session can influence concentrations. A pre-dialysis value, an immediate post-dialysis value, and an interdialytic value do not answer the same question.
Residual kidney function also varies widely among dialysis patients and can contribute meaningfully to clearance. Two people receiving the same nominal dialysis schedule may therefore have different metabolite profiles. For educational interpretation, “on dialysis” is a starting context, not a complete explanation.
What this block changes in practice
The first interpretive correction is to stop treating the kidney as an afterthought added only when eGFR is severely reduced.
Kidney function should be assessed before assigning high homocysteine to an MTHFR variant, high MMA to vitamin B12 deficiency, or high SAH to a primary methylation disorder.
The second correction is to avoid the opposite error. A renal contribution does not exclude a coexisting deficiency. The goal is layered attribution, not replacement of one oversimplification with another.
Kidney function should be assessed before assigning high homocysteine to an MTHFR variant, high MMA to vitamin B12 deficiency, or high SAH to a primary methylation disorder.
The second correction is to avoid the opposite error. A renal contribution does not exclude a coexisting deficiency. The goal is layered attribution, not replacement of one oversimplification with another.
What Happens to the Methionine Cycle When Kidney Function Declines
The cycle in its simplest useful form
Methionine is activated by methionine adenosyltransferase to form S-adenosylmethionine (SAM), the principal methyl donor for a large number of reactions.
After a methyltransferase transfers the methyl group, SAM becomes S-adenosylhomocysteine (SAH). SAH is then reversibly hydrolyzed to homocysteine and adenosine.
Homocysteine may be remethylated to methionine through the folate and vitamin B12-dependent methionine synthase pathway, or through the betaine-dependent BHMT pathway in tissues where BHMT is expressed. It may also enter the vitamin B6-dependent transsulfuration pathway through cystathionine beta-synthase.
The SAH hydrolase reaction is reversible and thermodynamically favors SAH synthesis. Efficient removal of homocysteine and adenosine is therefore important for continued SAH breakdown. When SAH accumulates, it can inhibit many methyltransferases.
This is why SAH and the SAM-to-SAH ratio are often discussed as indicators of methylation potential. However, plasma concentrations are not equivalent to intracellular concentrations in every tissue, and the ratio does not quantify all methylation reactions.
After a methyltransferase transfers the methyl group, SAM becomes S-adenosylhomocysteine (SAH). SAH is then reversibly hydrolyzed to homocysteine and adenosine.
Homocysteine may be remethylated to methionine through the folate and vitamin B12-dependent methionine synthase pathway, or through the betaine-dependent BHMT pathway in tissues where BHMT is expressed. It may also enter the vitamin B6-dependent transsulfuration pathway through cystathionine beta-synthase.
The SAH hydrolase reaction is reversible and thermodynamically favors SAH synthesis. Efficient removal of homocysteine and adenosine is therefore important for continued SAH breakdown. When SAH accumulates, it can inhibit many methyltransferases.
This is why SAH and the SAM-to-SAH ratio are often discussed as indicators of methylation potential. However, plasma concentrations are not equivalent to intracellular concentrations in every tissue, and the ratio does not quantify all methylation reactions.
Why homocysteine rises
Hyperhomocysteinemia becomes more common as kidney function declines and is especially frequent in dialysis populations.
Several mechanisms have been proposed and measured: lower metabolic clearance, reduced remethylation, reduced methionine transmethylation, disturbance of folate and vitamin B12 metabolism, inhibition by retained compounds, oxidative and inflammatory changes, altered protein and amino acid metabolism, and nutritional factors.
Stable-isotope studies have been particularly important because they show that the abnormality is not explained by urinary retention alone.
In a stable-isotope comparison of healthy participants and people with ESKD, homocysteine clearance and methylation flux were altered, and SAH was associated with the metabolic disturbance.
Reviews of this work conclude that whole-body remethylation and transmethylation are reduced in renal failure, while the evidence for transsulfuration is more complex. Some studies suggest that transsulfuration is relatively preserved, while downstream sulfur oxidation or metabolite clearance may be impaired.
This explains an important clinical paradox. Giving folate or vitamin B12 can lower homocysteine, yet the value often remains above the reference range. The residual elevation may not represent an untreated folate deficiency. It may reflect the renal metabolic environment, reduced clearance, altered flux, or a marker-response ceiling. The same principle applies to interpreting a partial response to trimethylglycine or other methyl donors.
Several mechanisms have been proposed and measured: lower metabolic clearance, reduced remethylation, reduced methionine transmethylation, disturbance of folate and vitamin B12 metabolism, inhibition by retained compounds, oxidative and inflammatory changes, altered protein and amino acid metabolism, and nutritional factors.
Stable-isotope studies have been particularly important because they show that the abnormality is not explained by urinary retention alone.
In a stable-isotope comparison of healthy participants and people with ESKD, homocysteine clearance and methylation flux were altered, and SAH was associated with the metabolic disturbance.
Reviews of this work conclude that whole-body remethylation and transmethylation are reduced in renal failure, while the evidence for transsulfuration is more complex. Some studies suggest that transsulfuration is relatively preserved, while downstream sulfur oxidation or metabolite clearance may be impaired.
This explains an important clinical paradox. Giving folate or vitamin B12 can lower homocysteine, yet the value often remains above the reference range. The residual elevation may not represent an untreated folate deficiency. It may reflect the renal metabolic environment, reduced clearance, altered flux, or a marker-response ceiling. The same principle applies to interpreting a partial response to trimethylglycine or other methyl donors.
SAM and SAH may rise together
In ESKD, both SAM and SAH can be elevated. A person may therefore have a high SAM concentration but a low SAM-to-SAH ratio because SAH has risen much more.
This is one reason the statement “high SAM means strong methylation” is unreliable. SAM supply is only one side of the reaction environment. Product inhibition by SAH, tissue distribution, enzyme activity, and substrate-specific regulation matter as well.
Published clinical example 2: high SAM did not mean a favorable methylation environment
Loehrer et al., 1998, 25 hemodialysis patients and 40 healthy controls.
Mean plasma homocysteine, SAM, and SAH were markedly higher in the dialysis group. SAM was approximately 381 nmol/L in patients versus 60 nmol/L in controls, while SAH was approximately 1,074 nmol/L versus 24.4 nmol/L. The mean plasma SAM-to-SAH ratio was approximately 0.36 in patients and 2.7 in controls.
Interpretation: The striking finding was not a shortage of circulating SAM. It was disproportionate SAH accumulation and a much lower ratio. The study supports disturbed transmethylation chemistry in ESKD, but it does not validate the plasma ratio as a stand-alone diagnosis of global tissue hypomethylation.
This is one reason the statement “high SAM means strong methylation” is unreliable. SAM supply is only one side of the reaction environment. Product inhibition by SAH, tissue distribution, enzyme activity, and substrate-specific regulation matter as well.
Published clinical example 2: high SAM did not mean a favorable methylation environment
Loehrer et al., 1998, 25 hemodialysis patients and 40 healthy controls.
Mean plasma homocysteine, SAM, and SAH were markedly higher in the dialysis group. SAM was approximately 381 nmol/L in patients versus 60 nmol/L in controls, while SAH was approximately 1,074 nmol/L versus 24.4 nmol/L. The mean plasma SAM-to-SAH ratio was approximately 0.36 in patients and 2.7 in controls.
Interpretation: The striking finding was not a shortage of circulating SAM. It was disproportionate SAH accumulation and a much lower ratio. The study supports disturbed transmethylation chemistry in ESKD, but it does not validate the plasma ratio as a stand-alone diagnosis of global tissue hypomethylation.
Evidence for impaired methylation reactions
Older mechanistic studies found impaired methyl esterification of erythrocyte membrane proteins in chronic renal failure, together with increased intracellular SAH.
Follow-up work examined how SAH accumulated in erythrocytes and reinforced the concept of endogenous methyltransferase inhibition in uremia.
These studies are valuable because they connect an altered metabolite to a measured methylation reaction rather than relying only on a plasma ratio.
The limitation is scope. Erythrocyte membrane protein methylation is one reaction in one cell type. It cannot be generalized to DNA methylation, neurotransmitter metabolism, phosphatidylcholine synthesis, creatine synthesis, catecholamine methylation, or every other SAM-dependent process.
Contemporary epigenetic studies in CKD describe widespread methylation differences, but those patterns may reflect cell composition, inflammation, medications, diabetes, age, toxin exposure, and disease severity in addition to SAM and SAH.
Follow-up work examined how SAH accumulated in erythrocytes and reinforced the concept of endogenous methyltransferase inhibition in uremia.
These studies are valuable because they connect an altered metabolite to a measured methylation reaction rather than relying only on a plasma ratio.
The limitation is scope. Erythrocyte membrane protein methylation is one reaction in one cell type. It cannot be generalized to DNA methylation, neurotransmitter metabolism, phosphatidylcholine synthesis, creatine synthesis, catecholamine methylation, or every other SAM-dependent process.
Contemporary epigenetic studies in CKD describe widespread methylation differences, but those patterns may reflect cell composition, inflammation, medications, diabetes, age, toxin exposure, and disease severity in addition to SAM and SAH.
Plasma, cells, and tissues are not interchangeable
SAM and SAH are labile metabolites with demanding pre-analytical requirements.
Plasma values are used mainly in research and are not standardized as routine diagnostic tools. Intracellular ratios can differ from plasma ratios.
Different tissues have different methyltransferases, transport systems, demands, and regulatory controls. A low plasma SAM-to-SAH ratio may support a disturbed transmethylation environment, particularly in advanced kidney disease, but it does not provide a universal percentage of methylation capacity.
The 2025 CARE FOR HOMe analysis measured homocysteine, SAH, and SAM in a CKD cohort and examined cardiovascular events.
Associations with outcomes were substantially explained by renal function. This is a useful corrective to causal overinterpretation: one-carbon metabolites may be markers of disease severity and renal clearance as much as independent drivers.
Plasma values are used mainly in research and are not standardized as routine diagnostic tools. Intracellular ratios can differ from plasma ratios.
Different tissues have different methyltransferases, transport systems, demands, and regulatory controls. A low plasma SAM-to-SAH ratio may support a disturbed transmethylation environment, particularly in advanced kidney disease, but it does not provide a universal percentage of methylation capacity.
The 2025 CARE FOR HOMe analysis measured homocysteine, SAH, and SAM in a CKD cohort and examined cardiovascular events.
Associations with outcomes were substantially explained by renal function. This is a useful corrective to causal overinterpretation: one-carbon metabolites may be markers of disease severity and renal clearance as much as independent drivers.
| Finding | What it may indicate | What it does not prove |
|---|---|---|
| High homocysteine | Reduced kidney-associated clearance or flux, nutrient deficiency, hypothyroidism, medication effect, inflammation, or combinations | A specific MTHFR defect, folate deficiency, or a need for methyl donors. |
| High SAM | Altered plasma distribution or accumulation; high substrate availability in that compartment | Efficient methylation in all tissues. |
| High SAH | Product accumulation and possible inhibition of some methyltransferases | Uniform inhibition of every methylation reaction. |
| Low SAM-to-SAH ratio | Disturbed transmethylation environment, especially when SAH is markedly elevated | A validated clinical diagnosis of “undermethylation.” |
| Homocysteine falls with vitamins | Biochemical responsiveness of the marker | Correction of the entire renal mechanism or improved cardiovascular outcomes. |
Genetic variants do not replace the renal explanation
Variants in MTHFR, MTR, MTRR, CBS, or BHMT may influence one-carbon metabolism, but common polymorphisms usually have modest effects compared with advanced renal dysfunction, nutritional deficiency, or medication exposure.
In a person with falling eGFR and rising homocysteine, finding an MTHFR C677T variant does not establish that the variant is the dominant cause. Genetic information is most useful when integrated with phenotype, not when used to override the stronger physiological determinant.
In a person with falling eGFR and rising homocysteine, finding an MTHFR C677T variant does not establish that the variant is the dominant cause. Genetic information is most useful when integrated with phenotype, not when used to override the stronger physiological determinant.
Why the SAH hydrolase reaction is central
S-adenosylhomocysteine hydrolase catalyzes a reversible reaction between S-adenosylhomocysteine and homocysteine plus adenosine.
In intact cells, rapid removal of homocysteine and adenosine usually pulls the reaction toward hydrolysis. When either product accumulates, the equilibrium can shift toward S-adenosylhomocysteine formation.
This explains why S-adenosylhomocysteine can rise disproportionately even when S-adenosylmethionine is also high. The relevant biochemical problem is not simply a lack of donor. It is product inhibition within a coupled system.
This chemistry also explains why adding more methyl donors is not an automatic solution. Increasing S-adenosylmethionine supply may support some reactions when donor availability is genuinely limiting, but it does not directly remove S-adenosylhomocysteine.
If product clearance is impaired, more substrate may increase flux into a bottleneck without restoring the ratio in the intended compartment. No routine clinical trial has established S-adenosylmethionine supplementation as a correction for the renal pattern.
In intact cells, rapid removal of homocysteine and adenosine usually pulls the reaction toward hydrolysis. When either product accumulates, the equilibrium can shift toward S-adenosylhomocysteine formation.
This explains why S-adenosylhomocysteine can rise disproportionately even when S-adenosylmethionine is also high. The relevant biochemical problem is not simply a lack of donor. It is product inhibition within a coupled system.
This chemistry also explains why adding more methyl donors is not an automatic solution. Increasing S-adenosylmethionine supply may support some reactions when donor availability is genuinely limiting, but it does not directly remove S-adenosylhomocysteine.
If product clearance is impaired, more substrate may increase flux into a bottleneck without restoring the ratio in the intended compartment. No routine clinical trial has established S-adenosylmethionine supplementation as a correction for the renal pattern.
Flux is different from concentration
A concentration is a snapshot of the amount present in a sampled compartment.
Flux describes the rate at which material moves through a pathway.
A high concentration can occur because production is high, utilization is low, export is reduced, clearance is reduced, or several of these occur together.
Conversely, a normal concentration can be maintained despite impaired flux if production and removal fall in parallel. Stable-isotope studies are valuable because they estimate pathway rates rather than relying only on concentrations.
In end-stage kidney disease, reduced remethylation and transmethylation flux has been demonstrated even though plasma methionine or S-adenosylmethionine may not be low.
This is the clearest answer to the common question, “How can the donor look adequate while methylation potential looks impaired?”
The pool size and the turnover of the pool are different variables.
Flux describes the rate at which material moves through a pathway.
A high concentration can occur because production is high, utilization is low, export is reduced, clearance is reduced, or several of these occur together.
Conversely, a normal concentration can be maintained despite impaired flux if production and removal fall in parallel. Stable-isotope studies are valuable because they estimate pathway rates rather than relying only on concentrations.
In end-stage kidney disease, reduced remethylation and transmethylation flux has been demonstrated even though plasma methionine or S-adenosylmethionine may not be low.
This is the clearest answer to the common question, “How can the donor look adequate while methylation potential looks impaired?”
The pool size and the turnover of the pool are different variables.
Remethylation and transsulfuration do not fail in identical ways
Homocysteine has two principal metabolic exits.
Remethylation returns it to methionine through the folate and vitamin B12-dependent methionine synthase pathway or, mainly in liver and kidney, through betaine-homocysteine methyltransferase.
Transsulfuration directs it toward cystathionine and cysteine through vitamin B6-dependent enzymes.
Studies of renal failure have not shown a simple uniform shutdown of both pathways. Earlier kinetic work reported a substantial reduction in remethylation, while transsulfuration findings were more variable.
The distinction matters because a high homocysteine result cannot identify which route is most responsible. Folate, vitamin B12, vitamin B6, betaine, methionine intake, renal metabolic clearance, and the uremic environment influence different parts of the network.
A response to folate or vitamin B12 demonstrates that the concentration can be moved through a vitamin-responsive route. It does not show that reduced vitamin supply was the only cause.
Remethylation returns it to methionine through the folate and vitamin B12-dependent methionine synthase pathway or, mainly in liver and kidney, through betaine-homocysteine methyltransferase.
Transsulfuration directs it toward cystathionine and cysteine through vitamin B6-dependent enzymes.
Studies of renal failure have not shown a simple uniform shutdown of both pathways. Earlier kinetic work reported a substantial reduction in remethylation, while transsulfuration findings were more variable.
The distinction matters because a high homocysteine result cannot identify which route is most responsible. Folate, vitamin B12, vitamin B6, betaine, methionine intake, renal metabolic clearance, and the uremic environment influence different parts of the network.
A response to folate or vitamin B12 demonstrates that the concentration can be moved through a vitamin-responsive route. It does not show that reduced vitamin supply was the only cause.
What the SAM-to-SAH ratio can and cannot support
The S-adenosylmethionine-to-S-adenosylhomocysteine ratio is often described as methylation potential because many methyltransferases are sensitive to both substrate and product.
The phrase is useful as biochemical shorthand, but it can be misunderstood as a universal score. Different enzymes have different affinities, product sensitivities, cellular locations, and regulatory inputs.
A ratio measured in plasma does not reproduce the ratio in liver, brain, kidney, immune cells, or erythrocytes.
The ratio is therefore strongest as a research indicator of a disturbed transmethylation environment, particularly when S-adenosylhomocysteine is markedly elevated in advanced renal disease.
It is weaker as a stand-alone explanation for fatigue, mood symptoms, drug responses, or broad labels such as under-methylation. There are no accepted clinical cutoffs that map a plasma ratio to a specific symptom burden or supplement dose.
The phrase is useful as biochemical shorthand, but it can be misunderstood as a universal score. Different enzymes have different affinities, product sensitivities, cellular locations, and regulatory inputs.
A ratio measured in plasma does not reproduce the ratio in liver, brain, kidney, immune cells, or erythrocytes.
The ratio is therefore strongest as a research indicator of a disturbed transmethylation environment, particularly when S-adenosylhomocysteine is markedly elevated in advanced renal disease.
It is weaker as a stand-alone explanation for fatigue, mood symptoms, drug responses, or broad labels such as under-methylation. There are no accepted clinical cutoffs that map a plasma ratio to a specific symptom burden or supplement dose.
Uremia can affect methylation beyond donor and product levels
Advanced kidney disease exposes cells to retained solutes, oxidative stress, inflammation, acid-base disturbances, altered redox state, and endocrine changes.
These factors can influence gene expression, enzyme activity, membrane composition, and epigenetic regulation. Observed DNA methylation differences in CKD may therefore arise through multiple pathways. S-adenosylhomocysteine is one plausible contributor, but it should not be treated as the sole cause of the epigenetic landscape.
This broader view prevents two opposite errors.
The first is to dismiss renal one-carbon changes as meaningless retention.
The second is to attribute every molecular change in CKD to a single methylation bottleneck. The evidence supports a network disturbance with several interacting determinants.
Published clinical example 3: concentrations and pathway rates told different parts of the story
Stam et al., 2004, stable-isotope study in healthy participants and people with end-stage renal disease.
The investigators quantified homocysteine clearance and methionine-cycle fluxes.
End-stage renal disease was associated with impaired homocysteine clearance through remethylation and transsulfuration and with reduced remethylation and transmethylation flux.
Whole-blood S-adenosylhomocysteine was related to impaired flux.
Interpretation: The study shows why a concentration-only model is incomplete. The renal pattern involves slower pathway turnover and altered product handling, not merely a high number waiting to be filtered.
These factors can influence gene expression, enzyme activity, membrane composition, and epigenetic regulation. Observed DNA methylation differences in CKD may therefore arise through multiple pathways. S-adenosylhomocysteine is one plausible contributor, but it should not be treated as the sole cause of the epigenetic landscape.
This broader view prevents two opposite errors.
The first is to dismiss renal one-carbon changes as meaningless retention.
The second is to attribute every molecular change in CKD to a single methylation bottleneck. The evidence supports a network disturbance with several interacting determinants.
Published clinical example 3: concentrations and pathway rates told different parts of the story
Stam et al., 2004, stable-isotope study in healthy participants and people with end-stage renal disease.
The investigators quantified homocysteine clearance and methionine-cycle fluxes.
End-stage renal disease was associated with impaired homocysteine clearance through remethylation and transsulfuration and with reduced remethylation and transmethylation flux.
Whole-blood S-adenosylhomocysteine was related to impaired flux.
Interpretation: The study shows why a concentration-only model is incomplete. The renal pattern involves slower pathway turnover and altered product handling, not merely a high number waiting to be filtered.
The responsible conclusion
Kidney failure can create a genuine disturbance in methionine-cycle flux and a biochemical environment characterized by high homocysteine, high SAH, altered SAM, and a lower SAM-to-SAH ratio. This is more than a laboratory artifact.
At the same time, routine clinical diagnosis cannot be built from these research markers alone. The most defensible use of the evidence is to recognize a secondary renal modifier of transmethylation, not to label the person with a separate primary methylation disorder.
At the same time, routine clinical diagnosis cannot be built from these research markers alone. The most defensible use of the evidence is to recognize a secondary renal modifier of transmethylation, not to label the person with a separate primary methylation disorder.
Beyond Homocysteine: Other Metabolites Affected by Kidney Function
Methylmalonic acid: related to vitamin B12, but not a direct methionine-cycle metabolite
Methylmalonic acid (MMA) rises when the vitamin B12-dependent conversion of methylmalonyl-CoA to succinyl-CoA is impaired.
It is therefore used as a functional marker of vitamin B12 status. MMA does not sit directly inside the methionine cycle, but it is frequently paired with homocysteine because vitamin B12 participates in both methylmalonyl-CoA mutase and methionine synthase pathways.
The diagnostic difficulty is that MMA also rises as kidney function declines.
The renal effect is not a small technical footnote. In older adults and in CKD, kidney function can explain a substantial portion of MMA variation.
Population studies have shown associations between MMA, eGFR, CKD severity, cognitive function, and mortality. These associations do not prove that MMA is a causal uremic toxin or that all elevated values are false-positive vitamin B12 results.
They show that MMA integrates several biological signals: vitamin B12-dependent metabolism, renal function, endogenous propionate production, age, and possibly gut microbial and mitochondrial factors.
It is therefore used as a functional marker of vitamin B12 status. MMA does not sit directly inside the methionine cycle, but it is frequently paired with homocysteine because vitamin B12 participates in both methylmalonyl-CoA mutase and methionine synthase pathways.
The diagnostic difficulty is that MMA also rises as kidney function declines.
The renal effect is not a small technical footnote. In older adults and in CKD, kidney function can explain a substantial portion of MMA variation.
Population studies have shown associations between MMA, eGFR, CKD severity, cognitive function, and mortality. These associations do not prove that MMA is a causal uremic toxin or that all elevated values are false-positive vitamin B12 results.
They show that MMA integrates several biological signals: vitamin B12-dependent metabolism, renal function, endogenous propionate production, age, and possibly gut microbial and mitochondrial factors.
Can MMA still help identify vitamin B12 deficiency in dialysis?
Yes, but not through a universal non-renal cutoff.
Small dialysis studies have used response to vitamin B12 as an external indicator. In one study, an MMA threshold around 750 nmol/L, combined with holotranscobalamin, helped identify participants whose MMA decreased after intramuscular vitamin B12.
The sample was small, and the approach has not become a universal standard. A 2024 review concluded that diagnosis in dialysis remains difficult and that no single marker is fully satisfactory.
Published clinical example 4: a high MMA threshold was explored in ESKD
Iqbal et al., 2013, 17 dialysis patients. Participants received 1 mg intramuscular vitamin B12 monthly for three months. MMA had the strongest predictive potential in receiver-operating analysis. Ten participants with pre-treatment MMA above 750 nmol/L and holotranscobalamin below 260 pmol/L had a mean MMA reduction of 461 nmol/L after supplementation.
Interpretation: This supports the possibility of metabolically responsive vitamin B12 insufficiency within ESKD, but the threshold came from a very small cohort and should not be treated as a general diagnostic rule.
Small dialysis studies have used response to vitamin B12 as an external indicator. In one study, an MMA threshold around 750 nmol/L, combined with holotranscobalamin, helped identify participants whose MMA decreased after intramuscular vitamin B12.
The sample was small, and the approach has not become a universal standard. A 2024 review concluded that diagnosis in dialysis remains difficult and that no single marker is fully satisfactory.
Published clinical example 4: a high MMA threshold was explored in ESKD
Iqbal et al., 2013, 17 dialysis patients. Participants received 1 mg intramuscular vitamin B12 monthly for three months. MMA had the strongest predictive potential in receiver-operating analysis. Ten participants with pre-treatment MMA above 750 nmol/L and holotranscobalamin below 260 pmol/L had a mean MMA reduction of 461 nmol/L after supplementation.
Interpretation: This supports the possibility of metabolically responsive vitamin B12 insufficiency within ESKD, but the threshold came from a very small cohort and should not be treated as a general diagnostic rule.
Serum vitamin B12 and holotranscobalamin
Serum total vitamin B12 measures cobalamin bound mainly to haptocorrin and transcobalamin. Holotranscobalamin represents the fraction bound to transcobalamin and available for cellular uptake. In theory, holotranscobalamin should be closer to biologically available vitamin B12.
In practice, both markers have limitations, and renal impairment can affect transport proteins and concentrations. Some studies found total vitamin B12 and holotranscobalamin less dependent on kidney function than MMA and homocysteine, while dialysis literature remains inconsistent.
A normal or high serum vitamin B12 concentration does not by itself prove adequate intracellular function, especially after supplementation. It also does not prove a “functional deficiency.”
The term functional deficiency should be reserved for a coherent pattern supported by clinical context, multiple biomarkers, treatment response, or a defined metabolic disorder, not used as an automatic explanation for any symptom with a normal serum result.
In practice, both markers have limitations, and renal impairment can affect transport proteins and concentrations. Some studies found total vitamin B12 and holotranscobalamin less dependent on kidney function than MMA and homocysteine, while dialysis literature remains inconsistent.
A normal or high serum vitamin B12 concentration does not by itself prove adequate intracellular function, especially after supplementation. It also does not prove a “functional deficiency.”
The term functional deficiency should be reserved for a coherent pattern supported by clinical context, multiple biomarkers, treatment response, or a defined metabolic disorder, not used as an automatic explanation for any symptom with a normal serum result.
Cystathionine: a crossing point between vitamin B6 and renal function
Cystathionine is produced when cystathionine beta-synthase condenses homocysteine with serine. It is then converted to cysteine by cystathionine gamma-lyase.
Both enzymes require pyridoxal 5-phosphate, the active coenzyme form of vitamin B6.
Elevated cystathionine can therefore be associated with vitamin B6 insufficiency. It also rises markedly in renal insufficiency, which compromises its specificity.
In renal populations, a high cystathionine value may reflect reduced clearance, altered distal transsulfuration, vitamin B6 status, or combinations.
The response to vitamin treatment may be incomplete. This means that cystathionine cannot be read as a simple “B6 marker” in CKD. If a vitamin B6 intervention is considered, the safety of chronic high-dose pyridoxine must also be recognized because pyridoxine excess can itself cause sensory neuropathy.
Both enzymes require pyridoxal 5-phosphate, the active coenzyme form of vitamin B6.
Elevated cystathionine can therefore be associated with vitamin B6 insufficiency. It also rises markedly in renal insufficiency, which compromises its specificity.
In renal populations, a high cystathionine value may reflect reduced clearance, altered distal transsulfuration, vitamin B6 status, or combinations.
The response to vitamin treatment may be incomplete. This means that cystathionine cannot be read as a simple “B6 marker” in CKD. If a vitamin B6 intervention is considered, the safety of chronic high-dose pyridoxine must also be recognized because pyridoxine excess can itself cause sensory neuropathy.
Cystathionine: a crossing point between vitamin B6 and renal function
Cystathionine is produced when cystathionine beta-synthase condenses homocysteine with serine. It is then converted to cysteine by cystathionine gamma-lyase. Both enzymes require pyridoxal 5-phosphate, the active coenzyme form of vitamin B6.
Elevated cystathionine can therefore be associated with vitamin B6 insufficiency. It also rises markedly in renal insufficiency, which compromises its specificity.
In renal populations, a high cystathionine value may reflect reduced clearance, altered distal transsulfuration, vitamin B6 status, or combinations.
The response to vitamin treatment may be incomplete. This means that cystathionine cannot be read as a simple “B6 marker” in CKD. If a vitamin B6 intervention is considered, the safety of chronic high-dose pyridoxine must also be recognized because pyridoxine excess can itself cause sensory neuropathy.
Elevated cystathionine can therefore be associated with vitamin B6 insufficiency. It also rises markedly in renal insufficiency, which compromises its specificity.
In renal populations, a high cystathionine value may reflect reduced clearance, altered distal transsulfuration, vitamin B6 status, or combinations.
The response to vitamin treatment may be incomplete. This means that cystathionine cannot be read as a simple “B6 marker” in CKD. If a vitamin B6 intervention is considered, the safety of chronic high-dose pyridoxine must also be recognized because pyridoxine excess can itself cause sensory neuropathy.
Dimethylglycine and the betaine pathway
Betaine donates a methyl group to homocysteine through BHMT, producing methionine and dimethylglycine (DMG).
A rise in DMG can be interpreted superficially as evidence that the pathway is active. In chronic renal failure, however, DMG accumulates and may inhibit BHMT through product feedback.
This creates a more complex picture: elevated product concentration can coexist with reduced effective pathway flux.
Published clinical example 5: DMG accumulation and the BHMT pathway
McGregor et al., 2001, 33 dialysis patients, 33 non-dialysis chronic renal failure patients, and 33 controls. Plasma DMG increased as renal function declined and was two- to threefold higher in dialysis patients. Plasma betaine did not differ significantly between groups. DMG, the DMG-to-betaine ratio, and creatinine were independent predictors of total homocysteine.
Interpretation: The finding supports a model in which renal dysfunction alters both clearance and betaine-dependent remethylation. High DMG is not evidence that more betaine will necessarily normalize the pathway.
A rise in DMG can be interpreted superficially as evidence that the pathway is active. In chronic renal failure, however, DMG accumulates and may inhibit BHMT through product feedback.
This creates a more complex picture: elevated product concentration can coexist with reduced effective pathway flux.
Published clinical example 5: DMG accumulation and the BHMT pathway
McGregor et al., 2001, 33 dialysis patients, 33 non-dialysis chronic renal failure patients, and 33 controls. Plasma DMG increased as renal function declined and was two- to threefold higher in dialysis patients. Plasma betaine did not differ significantly between groups. DMG, the DMG-to-betaine ratio, and creatinine were independent predictors of total homocysteine.
Interpretation: The finding supports a model in which renal dysfunction alters both clearance and betaine-dependent remethylation. High DMG is not evidence that more betaine will necessarily normalize the pathway.
What betaine intervention studies show
A small study reported that betaine supplementation decreased post-methionine-load hyperhomocysteinemia in chronic renal failure.
This demonstrates biochemical responsiveness of the BHMT pathway. It does not establish long-term renal safety, a cardiovascular benefit, or a standard indication for self-treatment.
Betaine can increase methionine and DMG, affect osmotic balance, and interact with a metabolic environment already characterized by high DMG. The current evidence supports research interest, not routine protocolization.
This demonstrates biochemical responsiveness of the BHMT pathway. It does not establish long-term renal safety, a cardiovascular benefit, or a standard indication for self-treatment.
Betaine can increase methionine and DMG, affect osmotic balance, and interact with a metabolic environment already characterized by high DMG. The current evidence supports research interest, not routine protocolization.
Choline, phosphatidylcholine, and trimethylamine-related pathways
Choline is a precursor for phosphatidylcholine, acetylcholine, and betaine. In CKD, choline-related interpretation is complicated by dietary restriction, altered gut microbiota, hepatic phosphatidylcholine synthesis, and the accumulation of trimethylamine N-oxide.
Trimethylamine N-oxide is not a methylation-cycle marker, and its relationship to kidney disease is strongly confounded by renal clearance. It should not be added to a methylation panel as if it directly measured methyl-donor sufficiency.
Choline and betaine intake may still matter nutritionally, but their assessment requires the broader renal and cardiovascular context.
Trimethylamine N-oxide is not a methylation-cycle marker, and its relationship to kidney disease is strongly confounded by renal clearance. It should not be added to a methylation panel as if it directly measured methyl-donor sufficiency.
Choline and betaine intake may still matter nutritionally, but their assessment requires the broader renal and cardiovascular context.
Serine and glycine
Serine supplies one-carbon units to the folate cycle through serine hydroxymethyltransferase, producing glycine.
Metabolomic studies have identified lower serine and altered glycine-related pathways in people with reduced eGFR, and kidney metabolism may contribute to these changes.
These observations are biologically relevant but remain exploratory for individual clinical interpretation.
A low plasma serine result does not identify a renal one-carbon disorder, and commercial metabolomic reference ranges are not equivalent to validated diagnostic thresholds.
Metabolomic studies have identified lower serine and altered glycine-related pathways in people with reduced eGFR, and kidney metabolism may contribute to these changes.
These observations are biologically relevant but remain exploratory for individual clinical interpretation.
A low plasma serine result does not identify a renal one-carbon disorder, and commercial metabolomic reference ranges are not equivalent to validated diagnostic thresholds.
Metabolite interpretation in renal context
Renal influence and common interpretive traps for one-carbon metabolites.
| Metabolite | Renal influence | Main interpretive trap |
|---|---|---|
| MMA | Often rises as eGFR declines; also reflects B12-dependent metabolism and propionate production. | Calling every elevation vitamin B12 deficiency, or dismissing every elevation as renal. |
| Cystathionine | May accumulate; influenced by B6 status and transsulfuration. | Using it as a specific B6-deficiency marker in CKD. |
| DMG | Accumulates with renal failure and may inhibit BHMT. | Assuming high DMG proves strong betaine-dependent remethylation. |
| Betaine | May be normal, low, or altered depending on nutrition, renal handling, and disease context. | Assuming a plasma value alone defines methyl-donor sufficiency. |
| Choline | Affected by diet, liver metabolism, dialysis nutrition, and gut microbial pathways. | Treating choline-related metabolites as direct measures of methylation capacity. |
| Serine/glycine | Metabolomic associations with lower eGFR and renal metabolism. | Turning exploratory associations into individual diagnoses. |
Scroll horizontally to view all columns on small screens.
Why methylmalonic acid may remain elevated after treatment
When methylmalonic acid decreases after vitamin B12 treatment but remains above the general reference interval, several interpretations are possible.
A vitamin-responsive component may have improved while a renal component persisted. The dose, route, duration, adherence, timing of sampling, and baseline severity may also matter. In dialysis, a persistent elevation is not unexpected because the non-vitamin determinants have not disappeared.
The opposite pattern also requires caution. A fall in methylmalonic acid does not prove that every symptom was caused by vitamin B12 deficiency.
Biochemical response is strongest when accompanied by a coherent clinical context and, where applicable, improvement in objective hematologic or neurologic findings.
Small dialysis studies have sometimes shown a methylmalonic acid response without improvement in mean corpuscular volume or hemoglobin.
A vitamin-responsive component may have improved while a renal component persisted. The dose, route, duration, adherence, timing of sampling, and baseline severity may also matter. In dialysis, a persistent elevation is not unexpected because the non-vitamin determinants have not disappeared.
The opposite pattern also requires caution. A fall in methylmalonic acid does not prove that every symptom was caused by vitamin B12 deficiency.
Biochemical response is strongest when accompanied by a coherent clinical context and, where applicable, improvement in objective hematologic or neurologic findings.
Small dialysis studies have sometimes shown a methylmalonic acid response without improvement in mean corpuscular volume or hemoglobin.
Urinary MMA-to-creatinine ratio: an attempted solution with its own limitations
Urinary methylmalonic acid normalized to creatinine has been explored as a way to reduce the confounding effect of renal function on serum methylmalonic acid.
The concept is attractive because it evaluates excretion relative to urinary creatinine.
However, urinary creatinine itself varies with muscle mass, diet, collection quality, and renal function. Severe oliguria, dialysis, acute illness, and tubular dysfunction can further limit interpretation.
Available studies suggest potential diagnostic value in selected settings, but the urinary ratio is not a universally validated replacement for serum methylmalonic acid. It should be viewed as an additional research-supported tool rather than a definitive renal correction formula.
The concept is attractive because it evaluates excretion relative to urinary creatinine.
However, urinary creatinine itself varies with muscle mass, diet, collection quality, and renal function. Severe oliguria, dialysis, acute illness, and tubular dysfunction can further limit interpretation.
Available studies suggest potential diagnostic value in selected settings, but the urinary ratio is not a universally validated replacement for serum methylmalonic acid. It should be viewed as an additional research-supported tool rather than a definitive renal correction formula.
Cystathionine is not a simple transsulfuration-speed meter
A high cystathionine concentration can arise when production from homocysteine continues while conversion to cysteine or renal removal is relatively limited.
Vitamin B6 insufficiency can contribute because cystathionine gamma-lyase requires pyridoxal 5-phosphate. Yet the same value may rise because kidney function is reduced.
The result does not tell whether transsulfuration is globally fast, globally slow, or bottlenecked at its second step.
This distinction is especially important in online interpretations that equate high cystathionine with accelerated CBS activity.
Common CBS variants and isolated metabolite values do not establish a clinically important pathway upregulation.
In renal disease, the dominant signal may be altered clearance and vitamin handling rather than inherited overactivity.
Vitamin B6 insufficiency can contribute because cystathionine gamma-lyase requires pyridoxal 5-phosphate. Yet the same value may rise because kidney function is reduced.
The result does not tell whether transsulfuration is globally fast, globally slow, or bottlenecked at its second step.
This distinction is especially important in online interpretations that equate high cystathionine with accelerated CBS activity.
Common CBS variants and isolated metabolite values do not establish a clinically important pathway upregulation.
In renal disease, the dominant signal may be altered clearance and vitamin handling rather than inherited overactivity.
Betaine, DMG, and product feedback
Betaine-homocysteine methyltransferase transfers one methyl group from betaine to homocysteine, producing methionine and dimethylglycine.
Dimethylglycine is therefore both a pathway product and a marker influenced by renal clearance. In uremia, a high dimethylglycine-to-betaine ratio may reflect product accumulation and reduced effective turnover. Product inhibition provides a plausible explanation for why normal betaine availability can coexist with impaired betaine-dependent remethylation.
A small betaine trial showed that the pathway remains pharmacologically responsive, particularly after a methionine load. That result cannot be converted into a general rule that trimethylglycine is indicated whenever homocysteine is high.
The intervention changes several metabolites simultaneously, and long-term patient-important outcomes have not been established in CKD.
Dimethylglycine is therefore both a pathway product and a marker influenced by renal clearance. In uremia, a high dimethylglycine-to-betaine ratio may reflect product accumulation and reduced effective turnover. Product inhibition provides a plausible explanation for why normal betaine availability can coexist with impaired betaine-dependent remethylation.
A small betaine trial showed that the pathway remains pharmacologically responsive, particularly after a methionine load. That result cannot be converted into a general rule that trimethylglycine is indicated whenever homocysteine is high.
The intervention changes several metabolites simultaneously, and long-term patient-important outcomes have not been established in CKD.
Direct, indirect, and contextual markers
One-carbon metabolism markers — clinical reference
| Marker class | Examples | Best-supported use | Main limitation in kidney disease |
|---|---|---|---|
| Direct methionine-cycle intermediates | Methionine, homocysteine, SAM, SAH | Research characterization of remethylation and transmethylation | Concentration does not equal tissue flux; SAM and SAH assays are not standardized for routine diagnosis. |
| Related functional nutrient markers | MMA, holotranscobalamin, cystathionine | Support assessment of vitamin B12 or vitamin B6 status in context | Renal function changes sensitivity, specificity, and useful thresholds. |
| Pathway products or substrates | Betaine, DMG, choline, serine, glycine | Describe connected pathways and nutritional context | Affected by diet, liver metabolism, gut microbiota, dialysis, and clearance. |
| Renal context markers | Creatinine, cystatin C, eGFR, albuminuria | Estimate filtration, chronicity, and kidney damage | They do not directly measure one-carbon metabolism and each has non-renal determinants. |
Interpret in conjunction with renal function and clinical context.
A marker becomes more informative when its class and intended question are explicit.
Methylmalonic acid can support a vitamin B12 question, but it is not a direct methylation score.
S-adenosylhomocysteine can support a research question about product inhibition, but it is not a routine CKD diagnostic criterion.
Estimated glomerular filtration rate can explain part of the variation, but it cannot assign the rest to a vitamin deficiency by subtraction.
Methylmalonic acid can support a vitamin B12 question, but it is not a direct methylation score.
S-adenosylhomocysteine can support a research question about product inhibition, but it is not a routine CKD diagnostic criterion.
Estimated glomerular filtration rate can explain part of the variation, but it cannot assign the rest to a vitamin deficiency by subtraction.
Interpreting change across several metabolites
A multi-marker response can be more informative than a single response, but only when the markers are interpreted according to their mechanisms.
For example, vitamin B12 treatment may lower methylmalonic acid and homocysteine while leaving cystathionine or S-adenosylhomocysteine elevated.
This pattern would be compatible with correction of a vitamin-responsive component within an unchanged renal environment. It would not mean that the treatment failed completely or that all remaining abnormalities require higher doses.
Conversely, a lower homocysteine with rising methionine or dimethylglycine may indicate a shift in pathway distribution rather than global normalization.
The value of the panel lies in explaining what changed and what did not, not in forcing every result into a single good-or-bad methylation score.
For example, vitamin B12 treatment may lower methylmalonic acid and homocysteine while leaving cystathionine or S-adenosylhomocysteine elevated.
This pattern would be compatible with correction of a vitamin-responsive component within an unchanged renal environment. It would not mean that the treatment failed completely or that all remaining abnormalities require higher doses.
Conversely, a lower homocysteine with rising methionine or dimethylglycine may indicate a shift in pathway distribution rather than global normalization.
The value of the panel lies in explaining what changed and what did not, not in forcing every result into a single good-or-bad methylation score.
The responsible conclusion
Beyond homocysteine, kidney function influences a network of markers that are often marketed as nutrient or methylation indicators.
Their biological meanings remain real, but their specificity changes when renal function is reduced.
The most useful interpretation is marker-specific and layered: identify what the metabolite normally reflects, determine how strongly renal function affects it, look for independent evidence of nutrient deficiency, and avoid treating a biochemical response as proof of a clinical benefit.
Their biological meanings remain real, but their specificity changes when renal function is reduced.
The most useful interpretation is marker-specific and layered: identify what the metabolite normally reflects, determine how strongly renal function affects it, look for independent evidence of nutrient deficiency, and avoid treating a biochemical response as proof of a clinical benefit.
The Laboratory Pattern and Why It Is Easy to Misread
There is no single renal one-carbon laboratory
The proposed pattern is not defined by a fixed combination of values.
Some people have isolated hyperhomocysteinemia.
Others have high MMA, high cystathionine, or high SAH.
Dialysis patients may show marked abnormalities across several markers.
Early CKD may create only subtle shifts.
Nutritional deficiency, supplementation, anemia, inflammation, thyroid disease, liver disease, and medications can modify the same panel. The absence of a single signature is not a weakness of the biology; it is a warning against diagnostic shortcuts.
Some people have isolated hyperhomocysteinemia.
Others have high MMA, high cystathionine, or high SAH.
Dialysis patients may show marked abnormalities across several markers.
Early CKD may create only subtle shifts.
Nutritional deficiency, supplementation, anemia, inflammation, thyroid disease, liver disease, and medications can modify the same panel. The absence of a single signature is not a weakness of the biology; it is a warning against diagnostic shortcuts.
Common combinations and their competing explanations
The “normal B12” problem
Serum vitamin B12 has imperfect sensitivity and specificity.
A person can have neurologic symptoms without macrocytosis, and supplementation can raise serum concentrations rapidly.
However, it is equally incorrect to declare a functional deficiency whenever symptoms persist despite a normal value. In CKD, the usual confirmatory markers, MMA and homocysteine, are also confounded.
Diagnosis therefore becomes a synthesis of history, diet, medications, gastrointestinal risk, autoimmune gastritis, blood count, neurologic examination, serum vitamin B12 or holotranscobalamin, renal function, and response to an appropriately chosen intervention when clinically justified.
The phrase “my B12 is high, so why is my MMA high?” captures a real interpretive conflict. The answer may include supplementation, reduced renal clearance of MMA, altered binding proteins, or genuine cellular insufficiency, but no single one of these can be assumed from the pair of numbers alone.
A person can have neurologic symptoms without macrocytosis, and supplementation can raise serum concentrations rapidly.
However, it is equally incorrect to declare a functional deficiency whenever symptoms persist despite a normal value. In CKD, the usual confirmatory markers, MMA and homocysteine, are also confounded.
Diagnosis therefore becomes a synthesis of history, diet, medications, gastrointestinal risk, autoimmune gastritis, blood count, neurologic examination, serum vitamin B12 or holotranscobalamin, renal function, and response to an appropriately chosen intervention when clinically justified.
The phrase “my B12 is high, so why is my MMA high?” captures a real interpretive conflict. The answer may include supplementation, reduced renal clearance of MMA, altered binding proteins, or genuine cellular insufficiency, but no single one of these can be assumed from the pair of numbers alone.
The “high B12” problem
High total serum vitamin B12 is common after oral or injectable supplementation.
Without supplementation, it can be associated with liver disease, hematologic disorders, malignancy, inflammation, renal impairment, or increased binding proteins. Macro-B12, an immunoglobulin-bound form, can also contribute to persistent elevation.
A high value therefore should not be automatically treated as toxicity or as proof of excellent intracellular status.
It is a contextual finding. In a renal pattern, the primary mistake is to use high serum B12 to dismiss all concern, or to use high MMA to declare deficiency without evaluating kidney function and other explanations.
Without supplementation, it can be associated with liver disease, hematologic disorders, malignancy, inflammation, renal impairment, or increased binding proteins. Macro-B12, an immunoglobulin-bound form, can also contribute to persistent elevation.
A high value therefore should not be automatically treated as toxicity or as proof of excellent intracellular status.
It is a contextual finding. In a renal pattern, the primary mistake is to use high serum B12 to dismiss all concern, or to use high MMA to declare deficiency without evaluating kidney function and other explanations.
Timing after supplementation
Public discussions frequently ask how many days or weeks supplements must be stopped to obtain an “accurate” test.
There is no universal washout that restores a hypothetical untreated baseline for every marker.
Serum vitamin B12 may remain elevated after supplementation, especially after injections.
MMA and homocysteine may fall with effective treatment and can be altered by folate, vitamin B6, riboflavin, diet, and renal function.
Stopping clinically necessary treatment solely to recreate an abnormal test can be unsafe when deficiency is suspected.
The test question should be defined before collection: screening before treatment, assessing biochemical response, or investigating persistent symptoms are different tasks.
There is no universal washout that restores a hypothetical untreated baseline for every marker.
Serum vitamin B12 may remain elevated after supplementation, especially after injections.
MMA and homocysteine may fall with effective treatment and can be altered by folate, vitamin B6, riboflavin, diet, and renal function.
Stopping clinically necessary treatment solely to recreate an abnormal test can be unsafe when deficiency is suspected.
The test question should be defined before collection: screening before treatment, assessing biochemical response, or investigating persistent symptoms are different tasks.
Homocysteine is pre-analytically sensitive
After blood is drawn, blood cells continue to produce and release homocysteine.
If plasma is not separated promptly, concentrations can rise substantially, approximately 10% per hour in some studies.
Fasting status, posture, recent protein intake, and assay methods can also affect results.
A surprising isolated value should be interpreted with the collection and processing conditions in mind. Repeating the test under standardized conditions may be more informative than immediately building a supplement protocol around one number.
If plasma is not separated promptly, concentrations can rise substantially, approximately 10% per hour in some studies.
Fasting status, posture, recent protein intake, and assay methods can also affect results.
A surprising isolated value should be interpreted with the collection and processing conditions in mind. Repeating the test under standardized conditions may be more informative than immediately building a supplement protocol around one number.
eGFR reported as “greater than 60”
Some laboratories report eGFR only as “>60,” which hides meaningful variation between 61 and 110 mL/min/1.73 m².
This can make it difficult to examine relationships between renal function and MMA or homocysteine.
A reported eGFR above 60 also does not exclude albuminuria, structural kidney disease, or a creatinine estimate distorted by muscle mass. When marker interpretation depends strongly on renal function, the exact creatinine, equation, age, cystatin C when appropriate, and urine albumin-to-creatinine ratio can matter.
This can make it difficult to examine relationships between renal function and MMA or homocysteine.
A reported eGFR above 60 also does not exclude albuminuria, structural kidney disease, or a creatinine estimate distorted by muscle mass. When marker interpretation depends strongly on renal function, the exact creatinine, equation, age, cystatin C when appropriate, and urine albumin-to-creatinine ratio can matter.
Dialysis timing
Pre-dialysis and post-dialysis values are not interchangeable. Dialysis may remove some metabolites and water-soluble vitamins, change plasma volume, and alter concentrations through redistribution. The magnitude depends on membrane characteristics, modality, session length, frequency, and residual kidney function. A research result obtained immediately before dialysis should not be compared casually with a community laboratory result obtained the day after dialysis.
Published clinical example 6: several markers fell, but did not normalize equally
Obeid et al., 2005, 38 hyperhomocysteinemic hemodialysis patients. After each dialysis session for one month, participants received intravenous folic acid 5 mg, vitamin B6 50 mg, and vitamin B12 0.7 mg. Median homocysteine fell from 26.1 to 13.2 micromol/L. MMA fell by 28% and cystathionine by 26%, but neither normalized. Twenty weeks after withdrawal, homocysteine returned near baseline.
Interpretation: The three markers were responsive but behaved differently. This is evidence against interpreting them as interchangeable measures of one underlying “methylation level.”
Published clinical example 6: several markers fell, but did not normalize equally
Obeid et al., 2005, 38 hyperhomocysteinemic hemodialysis patients. After each dialysis session for one month, participants received intravenous folic acid 5 mg, vitamin B6 50 mg, and vitamin B12 0.7 mg. Median homocysteine fell from 26.1 to 13.2 micromol/L. MMA fell by 28% and cystathionine by 26%, but neither normalized. Twenty weeks after withdrawal, homocysteine returned near baseline.
Interpretation: The three markers were responsive but behaved differently. This is evidence against interpreting them as interchangeable measures of one underlying “methylation level.”
Reference intervals are not renal correction ranges
Most laboratory reference intervals are derived from populations that are not stratified finely by kidney function, dialysis status, age, supplement exposure, or assay platform. A result above the interval is therefore an observation, not a diagnosis. Some studies have proposed higher methylmalonic acid thresholds for dialysis populations, but these thresholds are cohort-specific and not universally adopted.
It is also unsafe to create an informal correction by multiplying a marker by estimated glomerular filtration rate or subtracting a presumed renal component. Relationships are not necessarily linear, and non-renal determinants remain substantial. Riphagen and colleagues found that vitamin B12, estimated glomerular filtration rate, age, and sex explained only part of methylmalonic acid variation. The unexplained portion should be treated as uncertainty, not automatically relabelled functional deficiency.
It is also unsafe to create an informal correction by multiplying a marker by estimated glomerular filtration rate or subtracting a presumed renal component. Relationships are not necessarily linear, and non-renal determinants remain substantial. Riphagen and colleagues found that vitamin B12, estimated glomerular filtration rate, age, and sex explained only part of methylmalonic acid variation. The unexplained portion should be treated as uncertainty, not automatically relabelled functional deficiency.
Analytical methods and laboratory comparability
Homocysteine and methylmalonic acid can be measured by different analytical platforms. S-adenosylmethionine and S-adenosylhomocysteine require particularly careful specimen handling because they are labile and because cellular release can alter measured values. Results from different laboratories may not be directly interchangeable. A trend is most interpretable when the same specimen type, laboratory, method, preparation, and timing are used.
This issue is often missed when a person compares a private metabolomics panel with a hospital laboratory result or combines plasma, serum, dried blood spot, and urine values in one graph. Different matrices answer different questions and may use different units. Unit errors are common in public discussions of methylmalonic acid because nmol/L and µmol/L differ by a factor of one thousand.
This issue is often missed when a person compares a private metabolomics panel with a hospital laboratory result or combines plasma, serum, dried blood spot, and urine values in one graph. Different matrices answer different questions and may use different units. Unit errors are common in public discussions of methylmalonic acid because nmol/L and µmol/L differ by a factor of one thousand.
Four common interpretive scenarios
Scenario A: high homocysteine, normal B12 and folate, stable CKD
The renal context is a credible contributor. Review pre-analytical handling, thyroid function, vitamin B6, medications, smoking, diet, and whether serum vitamin results were influenced by supplementation. An MTHFR result may modify the picture but does not replace the renal explanation.
Scenario B: high MMA, neurologic symptoms, eGFR 45
Kidney function reduces the specificity of MMA, but the symptoms and clinical risk factors may still justify a structured vitamin B12 assessment. Serum B12 or holotranscobalamin, diet, gastrointestinal history, medications, blood count, and neurologic findings become more important. The answer is not “renal, ignore it” or “MMA, definite deficiency.”
Scenario C: high serum B12 and high MMA after injections
Recent injections can keep serum B12 high. Persistent MMA may reflect renal function, incomplete biochemical response, timing, or another determinant. Escalating injections solely to normalize MMA may expose the person to continued treatment without a defined clinical target.
Scenario D: high SAM, very high SAH, low SAM-to-SAH ratio in dialysis
The pattern is consistent with published research on disturbed transmethylation in advanced renal failure. It is not evidence that the person needs more SAMe, and it does not quantify methylation in the brain or other tissues.
The renal context is a credible contributor. Review pre-analytical handling, thyroid function, vitamin B6, medications, smoking, diet, and whether serum vitamin results were influenced by supplementation. An MTHFR result may modify the picture but does not replace the renal explanation.
Scenario B: high MMA, neurologic symptoms, eGFR 45
Kidney function reduces the specificity of MMA, but the symptoms and clinical risk factors may still justify a structured vitamin B12 assessment. Serum B12 or holotranscobalamin, diet, gastrointestinal history, medications, blood count, and neurologic findings become more important. The answer is not “renal, ignore it” or “MMA, definite deficiency.”
Scenario C: high serum B12 and high MMA after injections
Recent injections can keep serum B12 high. Persistent MMA may reflect renal function, incomplete biochemical response, timing, or another determinant. Escalating injections solely to normalize MMA may expose the person to continued treatment without a defined clinical target.
Scenario D: high SAM, very high SAH, low SAM-to-SAH ratio in dialysis
The pattern is consistent with published research on disturbed transmethylation in advanced renal failure. It is not evidence that the person needs more SAMe, and it does not quantify methylation in the brain or other tissues.
Negative results do not close every question
Repeating a test is useful when the first result may have been affected by delayed processing, acute illness, recent supplementation, a changing creatinine concentration, or a different laboratory method. It is also useful when a treatment was started for a defined reason and the marker is part of the agreed monitoring plan.
Repetition becomes less useful when it is performed every few weeks without a stable protocol, when several interventions are changed simultaneously, or when the only goal is to force every value into a general-population interval.
A repeat result should answer a pre-specified question: Was the abnormality reproducible? Did it move in the expected direction? Did kidney function change at the same time? Did an objective clinical finding improve? Without a question, more testing can create more ambiguity rather than more knowledge.
Repetition becomes less useful when it is performed every few weeks without a stable protocol, when several interventions are changed simultaneously, or when the only goal is to force every value into a general-population interval.
A repeat result should answer a pre-specified question: Was the abnormality reproducible? Did it move in the expected direction? Did kidney function change at the same time? Did an objective clinical finding improve? Without a question, more testing can create more ambiguity rather than more knowledge.
What a repeat panel can and cannot show
Serial data can clarify whether a change tracks eGFR, supplementation, dialysis timing, dietary intake, or illness. A repeat panel is most useful when collection conditions are similar and the clinical question is explicit.
It cannot determine tissue methylation globally, prove causality, or separate all overlapping influences without additional information. A number that improves after treatment may validate biochemical responsiveness, but not necessarily the original causal story.
It cannot determine tissue methylation globally, prove causality, or separate all overlapping influences without additional information. A number that improves after treatment may validate biochemical responsiveness, but not necessarily the original causal story.
Distinguishing Renal Effects from Primary Nutrient and Methylation Problems
Begin with coexistence, not either-or thinking
Chronic kidney disease does not protect against vitamin B12, folate, vitamin B6, riboflavin, iron, or protein-energy deficiency. Dialysis, restricted diets, reduced appetite, gastrointestinal disease, medications, inflammation, and food insecurity may increase nutritional risk. The most common diagnostic error is therefore an either-or choice: “the marker is renal” versus “the marker is nutritional.” Both can be true.
A second error is to label every residual abnormality after vitamin treatment as an unresolved deficiency. In advanced CKD, a treated person may remain above population reference ranges because the renal component persists. Interpretation should ask whether there was independent evidence of deficiency, whether the intervention corrected that evidence, and whether further dose escalation has a justified target.
A second error is to label every residual abnormality after vitamin treatment as an unresolved deficiency. In advanced CKD, a treated person may remain above population reference ranges because the renal component persists. Interpretation should ask whether there was independent evidence of deficiency, whether the intervention corrected that evidence, and whether further dose escalation has a justified target.
A structured differential for high MMA
The key domains are vitamin B12 deficiency or impaired cellular use, reduced renal function, recent treatment, endogenous propionate production, age, and rare inborn errors.
In adults with known CKD, rare methylmalonic acidemia is generally not the default explanation for a modest elevation. Conversely, advanced neurologic symptoms with strong risk factors for vitamin B12 deficiency should not be dismissed because eGFR is reduced.
The clinical stakes and the pattern of evidence determine how aggressively deficiency is evaluated.
In adults with known CKD, rare methylmalonic acidemia is generally not the default explanation for a modest elevation. Conversely, advanced neurologic symptoms with strong risk factors for vitamin B12 deficiency should not be dismissed because eGFR is reduced.
The clinical stakes and the pattern of evidence determine how aggressively deficiency is evaluated.
Folate deficiency and folate markers
Serum folate responds quickly to recent intake, while red-cell folate reflects a longer period but has its own analytical limitations.
Folic acid fortification and supplement use reduce the prevalence of severe deficiency in some populations, but dialysis losses, restricted intake, alcohol exposure, malabsorption, and medications remain relevant.
High-dose folic acid can lower homocysteine without proving that folate deficiency was present. This is especially important in CKD trials, where pharmacologic doses were often used to test vascular hypotheses rather than to correct documented deficiency.
Folic acid fortification and supplement use reduce the prevalence of severe deficiency in some populations, but dialysis losses, restricted intake, alcohol exposure, malabsorption, and medications remain relevant.
High-dose folic acid can lower homocysteine without proving that folate deficiency was present. This is especially important in CKD trials, where pharmacologic doses were often used to test vascular hypotheses rather than to correct documented deficiency.
Vitamin B6 and riboflavin
Vitamin B6 status can affect cystathionine and transsulfuration.
Hemodialysis can alter water-soluble vitamin status, and some patients may have low pyridoxal 5-phosphate. Yet chronic high-dose pyridoxine can cause neuropathy, creating a dangerous interpretive loop when neuropathic symptoms are treated with escalating B6.
Riboflavin is a cofactor for MTHFR and can influence homocysteine particularly in people with the MTHFR 677TT genotype, but this genotype-specific effect has not established a renal methylation protocol.
Hemodialysis can alter water-soluble vitamin status, and some patients may have low pyridoxal 5-phosphate. Yet chronic high-dose pyridoxine can cause neuropathy, creating a dangerous interpretive loop when neuropathic symptoms are treated with escalating B6.
Riboflavin is a cofactor for MTHFR and can influence homocysteine particularly in people with the MTHFR 677TT genotype, but this genotype-specific effect has not established a renal methylation protocol.
Protein intake, methionine, and renal nutrition
A person with CKD may receive advice to reduce protein intake, while a person concerned about “low methylation” may be encouraged elsewhere to increase methionine or protein. These goals can conflict.
Protein recommendations depend on CKD stage, diabetes, dialysis status, nutritional state, age, and risk of protein-energy wasting. Dialysis usually increases protein requirements relative to non-dialysis CKD. The KDOQI nutrition guideline emphasizes individualized medical nutrition therapy rather than a universal high- or low-protein rule.
Low methionine can reflect low protein intake, malnutrition, liver disease, acute illness, or analytical variation.
High homocysteine in the same person does not automatically mean methionine should be supplemented.
Homocysteine concentration reflects recycling and clearance as well as precursor supply. Direct methionine supplementation can raise homocysteine and is not a neutral way to “feed SAM” in a person with renal impairment.
Protein recommendations depend on CKD stage, diabetes, dialysis status, nutritional state, age, and risk of protein-energy wasting. Dialysis usually increases protein requirements relative to non-dialysis CKD. The KDOQI nutrition guideline emphasizes individualized medical nutrition therapy rather than a universal high- or low-protein rule.
Low methionine can reflect low protein intake, malnutrition, liver disease, acute illness, or analytical variation.
High homocysteine in the same person does not automatically mean methionine should be supplemented.
Homocysteine concentration reflects recycling and clearance as well as precursor supply. Direct methionine supplementation can raise homocysteine and is not a neutral way to “feed SAM” in a person with renal impairment.
Thyroid, liver, inflammation, and anemia
Fatigue, cognitive slowing, weakness, neuropathy, and macrocytosis are not specific to one-carbon metabolism.
Thyroid disease can affect homocysteine and symptoms. Liver disease can change methionine handling, SAM synthesis, and serum B12.
Inflammation can alter cystatin C, nutrient biomarkers, albumin, iron distribution, and erythropoiesis.
Anemia in CKD is often multifactorial, involving erythropoietin deficiency, iron restriction, inflammation, blood loss, shortened red-cell survival, and sometimes folate or vitamin B12 deficiency.
Thyroid disease can affect homocysteine and symptoms. Liver disease can change methionine handling, SAM synthesis, and serum B12.
Inflammation can alter cystatin C, nutrient biomarkers, albumin, iron distribution, and erythropoiesis.
Anemia in CKD is often multifactorial, involving erythropoietin deficiency, iron restriction, inflammation, blood loss, shortened red-cell survival, and sometimes folate or vitamin B12 deficiency.
Medication review
Medication effects should be evaluated through specific mechanisms rather than a generic “depletes methyl groups” category.
Metformin and proton-pump inhibitors can increase the risk of vitamin B12 deficiency in susceptible people. Antiseizure drugs can affect folate.
Methotrexate directly interferes with folate metabolism. Renally cleared medications may accumulate and contribute to symptoms that are mistakenly attributed to methylation. Dialysis schedules and phosphate binders can affect nutrient timing and absorption. A medication list often explains more than a broad SNP panel.
Metformin and proton-pump inhibitors can increase the risk of vitamin B12 deficiency in susceptible people. Antiseizure drugs can affect folate.
Methotrexate directly interferes with folate metabolism. Renally cleared medications may accumulate and contribute to symptoms that are mistakenly attributed to methylation. Dialysis schedules and phosphate binders can affect nutrient timing and absorption. A medication list often explains more than a broad SNP panel.
Genetics: when it matters and when it distracts
Rare inherited disorders of homocysteine or methylmalonate metabolism can produce striking biochemical patterns and require specialist evaluation.
Common variants such as MTHFR C677T are different. They modify enzyme activity and can interact with folate and riboflavin status, but they do not diagnose a symptom syndrome, explain high MMA, or override renal function.
A common variant may be one layer in the model, not the organizing diagnosis.
Common variants such as MTHFR C677T are different. They modify enzyme activity and can interact with folate and riboflavin status, but they do not diagnose a symptom syndrome, explain high MMA, or override renal function.
A common variant may be one layer in the model, not the organizing diagnosis.
When creatinine and cystatin C disagree
Disagreement is information. A muscular person using creatine may have a lower creatinine-based eGFR than the cystatin C estimate without true loss of filtration. A frail person with low muscle mass may have deceptively reassuring creatinine. Inflammation or glucocorticoids can raise cystatin C. KDIGO supports using the combined estimate when greater accuracy matters. If an MMA or homocysteine interpretation changes materially depending on which eGFR is used, the uncertainty should be stated rather than hidden.
Applied interpretation example based on published evidence
Evidence base: Loikas 2007, Iqbal 2013, KDIGO 2024
A person has elevated MMA, normal total vitamin B12, and a creatinine-based eGFR near a diagnostic boundary. The evidence does not permit a direct choice between “B12 deficiency” and “renal retention.” A stronger evaluation would examine the persistence and accuracy of kidney-function estimates, albuminuria, B12 risk factors, blood count, neurologic findings, supplementation history, and possibly holotranscobalamin or a monitored therapeutic response.
Interpretation: This is not a fictional patient outcome. It is a demonstration of how the evidence changes the decision structure: the test result becomes a conditional clue rather than a diagnosis.
Applied interpretation example based on published evidence
Evidence base: Loikas 2007, Iqbal 2013, KDIGO 2024
A person has elevated MMA, normal total vitamin B12, and a creatinine-based eGFR near a diagnostic boundary. The evidence does not permit a direct choice between “B12 deficiency” and “renal retention.” A stronger evaluation would examine the persistence and accuracy of kidney-function estimates, albuminuria, B12 risk factors, blood count, neurologic findings, supplementation history, and possibly holotranscobalamin or a monitored therapeutic response.
Interpretation: This is not a fictional patient outcome. It is a demonstration of how the evidence changes the decision structure: the test result becomes a conditional clue rather than a diagnosis.
Coexisting deficiency is common enough to require active consideration
Renal influence and nutrient deficiency are not mutually exclusive. People with chronic kidney disease may have reduced appetite, restrictive diets, gastrointestinal disease, metformin or proton pump inhibitor exposure, inflammation, dialysis-related losses, repeated hospitalization, and limited access to varied food. Dialysis patients may receive routine renal multivitamins, but practices vary and supplementation can obscure serum testing.
The correct question is therefore not whether the marker is “renal or nutritional.” It is whether there is independent evidence for each component. A low serum vitamin B12, low holotranscobalamin, dietary risk, macrocytosis, hypersegmented neutrophils, anti-intrinsic-factor antibodies, or a coherent neurologic syndrome increases the probability of a true vitamin B12 problem. A stable inverse relationship with estimated glomerular filtration rate, absence of clinical risk factors, and lack of objective response increases the probability that the abnormal marker is largely renal or non-specific.
The correct question is therefore not whether the marker is “renal or nutritional.” It is whether there is independent evidence for each component. A low serum vitamin B12, low holotranscobalamin, dietary risk, macrocytosis, hypersegmented neutrophils, anti-intrinsic-factor antibodies, or a coherent neurologic syndrome increases the probability of a true vitamin B12 problem. A stable inverse relationship with estimated glomerular filtration rate, absence of clinical risk factors, and lack of objective response increases the probability that the abnormal marker is largely renal or non-specific.
A differential framework for serum vitamin B12 that is unexpectedly high
High serum vitamin B12 is usually explained first by supplements or injections. Without supplementation, the differential includes liver disease, myeloid and other hematologic disorders, malignancy, inflammation, renal impairment, altered binding proteins, and macro-B12. The result should be interpreted with the complete blood count, liver tests, renal measures, medication and supplement history, and the clinical reason the test was ordered. A high value is not itself a methylation diagnosis.
In kidney disease, high total vitamin B12 may coexist with high methylmalonic acid. This pair does not prove that vitamin B12 is trapped outside cells. It may reflect supplementation plus renal methylmalonic acid retention, altered transport proteins, or a genuine functional problem. The stronger the claim, the more independent support is required.
In kidney disease, high total vitamin B12 may coexist with high methylmalonic acid. This pair does not prove that vitamin B12 is trapped outside cells. It may reflect supplementation plus renal methylmalonic acid retention, altered transport proteins, or a genuine functional problem. The stronger the claim, the more independent support is required.
Diet cannot be inferred from one methionine or homocysteine result
Low protein intake can reduce methionine intake, but plasma methionine is tightly regulated and is influenced by fasting state, liver metabolism, catabolism, and recent food intake. High homocysteine does not prove excessive animal protein, and low homocysteine does not prove protein deficiency. In CKD, protein recommendations differ by stage, dialysis status, nutritional state, age, comorbidity, and treatment goals.
A person on dialysis usually has different protein needs from a person with non-dialysis CKD. Restricting methionine or total protein in response to a single methylation panel can worsen protein-energy wasting. Conversely, adding methionine or high-dose amino-acid products to “raise SAM” can be inappropriate in a person whose nitrogen, potassium, phosphorus, or acid load already requires careful management. Nutritional decisions should be based on renal nutrition assessment, not pathway symbolism.
A person on dialysis usually has different protein needs from a person with non-dialysis CKD. Restricting methionine or total protein in response to a single methylation panel can worsen protein-energy wasting. Conversely, adding methionine or high-dose amino-acid products to “raise SAM” can be inappropriate in a person whose nitrogen, potassium, phosphorus, or acid load already requires careful management. Nutritional decisions should be based on renal nutrition assessment, not pathway symbolism.
Genetics should answer a defined question
Common variants in MTHFR and other one-carbon genes can influence baseline metabolite concentrations, especially when nutrient status is marginal. Their effect is usually probabilistic, not diagnostic. A genotype does not reveal current folate status, kidney function, medication exposure, or pathway flux. It also does not identify the cause of a new rise in homocysteine when renal function has changed.
Rare inborn errors are different. Very high homocysteine, early thrombosis, developmental abnormalities, lens dislocation, unexplained neurologic disease, or characteristic metabolite patterns may warrant specialist metabolic or genetic evaluation. The presence of severe or unusual findings should not be managed through consumer single-nucleotide-polymorphism reports.
Rare inborn errors are different. Very high homocysteine, early thrombosis, developmental abnormalities, lens dislocation, unexplained neurologic disease, or characteristic metabolite patterns may warrant specialist metabolic or genetic evaluation. The presence of severe or unusual findings should not be managed through consumer single-nucleotide-polymorphism reports.
What a consumer genetic report can and cannot do
It can:
It cannot:
- identify common variants that may be worth discussing in context;
- generate questions about nutrient intake and family history;
- sometimes reveal a rare variant that requires confirmation in a clinical laboratory.
It cannot:
- measure enzyme activity in the liver;
- measure hepatic SAM or SAH;
- diagnose fatty liver or fibrosis;
- distinguish inherited from acquired expression changes;
- determine whether a supplement will help;
Markers and Similar Patterns
Interpret methionine, SAM, SAH, homocysteine, liver markers, and overlapping methylation patterns together
This is the block in which most interpretive errors occur.
A laboratory result feels concrete, but a concrete number can still be nonspecific.
The aim is not to collect the largest possible panel.
It is to understand what each marker measures, what it does not measure, and which combinations deserve a different level of attention.
A laboratory result feels concrete, but a concrete number can still be nonspecific.
The aim is not to collect the largest possible panel.
It is to understand what each marker measures, what it does not measure, and which combinations deserve a different level of attention.
Plasma methionine
Plasma methionine is usually measured as part of a plasma amino-acid profile.
It reflects the circulating pool at the time of collection.
It is influenced by:
What a high value can mean
A high methionine result can occur with:
The magnitude matters.
A small elevation on one nonfasting sample is not interpreted in the same way as persistent marked hypermethioninemia on repeated plasma amino-acid testing.
What a low value can mean
A low methionine result can occur with:
A low result does not prove that the liver cannot produce SAM.
Direct SAM measurement, accompanying amino acids, nutritional status, homocysteine, vitamin status, and clinical context are needed before locating the problem.
The common misunderstanding
“High methionine means I am eating too much protein” and “low methionine means I should take L-methionine” are both premature conclusions.
Methionine is a node, not a diagnosis.
It reflects the circulating pool at the time of collection.
It is influenced by:
- recent food intake;
- fasting duration;
- protein turnover;
- hepatic uptake;
- conversion to SAM;
- remethylation;
- transsulfuration;
- age;
- illness;
- inherited disorders.
What a high value can mean
A high methionine result can occur with:
- recent methionine or protein intake;
- MAT1A-related methionine adenosyltransferase I/III deficiency;
- GNMT deficiency;
- AHCY deficiency;
- adenosine kinase deficiency;
- CBS deficiency, usually with high total homocysteine;
- severe liver dysfunction;
- parenteral nutrition or specialized formulas;
- transient neonatal or illness-related changes;
- laboratory or pre-analytical factors.
The magnitude matters.
A small elevation on one nonfasting sample is not interpreted in the same way as persistent marked hypermethioninemia on repeated plasma amino-acid testing.
What a low value can mean
A low methionine result can occur with:
- low protein or methionine intake;
- malabsorption or inadequate total nutrition;
- catabolic illness;
- impaired remethylation;
- increased utilization or altered amino-acid balance;
- sample timing and laboratory variation.
A low result does not prove that the liver cannot produce SAM.
Direct SAM measurement, accompanying amino acids, nutritional status, homocysteine, vitamin status, and clinical context are needed before locating the problem.
The common misunderstanding
“High methionine means I am eating too much protein” and “low methionine means I should take L-methionine” are both premature conclusions.
Methionine is a node, not a diagnosis.
S-adenosylmethionine
S-adenosylmethionine can be measured in plasma, serum, whole blood, erythrocytes, cells, or tissue, depending on the research or specialist method.
These compartments are not interchangeable. SAM is labile, and analytical methods vary.
What a low value may suggest
A low SAM concentration may be consistent with:
It does not reveal which methylation reactions are affected.
It also does not automatically justify SAMe supplementation.
What a high value may suggest
A high SAM concentration may occur with:
High SAM does not equal globally high methylation.
If SAH is also high, methyltransferases may still be inhibited. If GNMT is deficient, SAM may accumulate because it is not being buffered normally.
The common misunderstanding
People often interpret SAM as if it were a fuel-gauge reading.
In reality, it is a dynamic metabolite distributed among many competing reactions. A pool size does not
directly measure flux.
These compartments are not interchangeable. SAM is labile, and analytical methods vary.
What a low value may suggest
A low SAM concentration may be consistent with:
- reduced methionine availability;
- impaired methionine-to-SAM conversion;
- high utilization relative to production;
- advanced liver dysfunction;
- specimen or analytical problems.
It does not reveal which methylation reactions are affected.
It also does not automatically justify SAMe supplementation.
What a high value may suggest
A high SAM concentration may occur with:
- GNMT deficiency or reduced buffering;
- AHCY or adenosine-related disorders;
- renal dysfunction;
- exogenous SAMe use;
- altered tissue export or distribution;
- selected metabolic and liver-disease contexts.
High SAM does not equal globally high methylation.
If SAH is also high, methyltransferases may still be inhibited. If GNMT is deficient, SAM may accumulate because it is not being buffered normally.
The common misunderstanding
People often interpret SAM as if it were a fuel-gauge reading.
In reality, it is a dynamic metabolite distributed among many competing reactions. A pool size does not
directly measure flux.
S-adenosylhomocysteine
S-adenosylhomocysteine is the product of SAM-dependent methyl transfer and an inhibitor of many methyltransferases.
It is particularly sensitive to disturbances in homocysteine, adenosine, and renal metabolism.
What an elevated value may suggest
An elevated value does not, by itself, identify the liver as the source.
Kidney function and the analytical method are essential parts of interpretation.
Why SAH can be more informative than homocysteine
Homocysteine is downstream of SAH and is rapidly routed into remethylation or transsulfuration.
SAH more directly reflects product inhibition of methyltransferases. In some research contexts, SAH correlates more strongly than homocysteine with impaired methylation potential.
However, its measurement is less standardized and less widely available.
It is particularly sensitive to disturbances in homocysteine, adenosine, and renal metabolism.
What an elevated value may suggest
- increased methyltransferase product load;
- impaired SAH hydrolysis or downstream removal;
- renal dysfunction;
- AHCY deficiency;
- adenosine kinase deficiency;
- altered liver metabolism;
- systemic metabolic or vascular disease.
An elevated value does not, by itself, identify the liver as the source.
Kidney function and the analytical method are essential parts of interpretation.
Why SAH can be more informative than homocysteine
Homocysteine is downstream of SAH and is rapidly routed into remethylation or transsulfuration.
SAH more directly reflects product inhibition of methyltransferases. In some research contexts, SAH correlates more strongly than homocysteine with impaired methylation potential.
However, its measurement is less standardized and less widely available.
The SAM/SAH ratio
The SAM/SAH ratio is frequently described as an index of methylation potential.
This description is biochemically reasonable, but several caveats are necessary.
A ratio is not a diagnosis
There is no universal cut-off that establishes hepatic methylation failure across all laboratories and populations.
Different studies use different:
A result must be interpreted against the laboratory’s validated reference interval.
Absolute values matter
A ratio of 3 can arise from:
These profiles have different implications.
Compartment matters
Plasma ratios do not necessarily represent:
Tissue SAM and plasma SAM can move differently in disease.
Timing and handling matter
SAM and SAH require:
A commercial panel should disclose the specimen, method, reference interval, and handling requirements.
The common misunderstanding
A low ratio is often treated as a signal to add methyl donors.
If the ratio is low because SAH is high, increasing methyl supply may not address the dominant constraint.
This description is biochemically reasonable, but several caveats are necessary.
A ratio is not a diagnosis
There is no universal cut-off that establishes hepatic methylation failure across all laboratories and populations.
Different studies use different:
- specimens;
- units;
- methods;
- disease groups.
A result must be interpreted against the laboratory’s validated reference interval.
Absolute values matter
A ratio of 3 can arise from:
- low SAM and modest SAH;
- normal SAM and high SAH;
- very high concentrations of both.
These profiles have different implications.
Compartment matters
Plasma ratios do not necessarily represent:
- hepatocyte cytosol;
- hepatocyte nuclei;
- mitochondria;
- other tissues.
Tissue SAM and plasma SAM can move differently in disease.
Timing and handling matter
SAM and SAH require:
- careful collection;
- rapid processing;
- appropriate temperature control;
- validated storage.
A commercial panel should disclose the specimen, method, reference interval, and handling requirements.
The common misunderstanding
A low ratio is often treated as a signal to add methyl donors.
If the ratio is low because SAH is high, increasing methyl supply may not address the dominant constraint.
Total homocysteine
Total homocysteine is the most commonly available marker in this network.
It includes several forms of homocysteine in plasma and is influenced by:
High homocysteine
Common contributors include:
Liver disease can contribute, but high homocysteine is not liver-specific.
Low homocysteine
Low total homocysteine is less well standardized as a clinical problem.
It can occur with:
It does not establish “overmethylation” or “CBS upregulation.”
Why normal homocysteine can be misleading
A normal value does not prove that SAM and SAH are normal.
Homocysteine is a branch point and can be maintained within range despite changes upstream. It also cannot exclude fatty liver, fibrosis, or altered hepatic gene expression.
It includes several forms of homocysteine in plasma and is influenced by:
- remethylation;
- transsulfuration;
- kidney function;
- age;
- genetics;
- vitamin status;
- thyroid function;
- smoking;
- alcohol;
- medication;
- illness.
High homocysteine
Common contributors include:
- folate deficiency;
- vitamin B12 deficiency;
- vitamin B6 deficiency;
- kidney dysfunction;
- hypothyroidism;
- smoking;
- selected medications;
- aging;
- common MTHFR variation in a low-folate context;
- inherited disorders such as CBS deficiency or severe remethylation disorders.
Liver disease can contribute, but high homocysteine is not liver-specific.
Low homocysteine
Low total homocysteine is less well standardized as a clinical problem.
It can occur with:
- low methionine intake;
- low protein status;
- pregnancy;
- high remethylation support;
- high transsulfuration demand;
- certain illnesses;
- analytical variation.
It does not establish “overmethylation” or “CBS upregulation.”
Why normal homocysteine can be misleading
A normal value does not prove that SAM and SAH are normal.
Homocysteine is a branch point and can be maintained within range despite changes upstream. It also cannot exclude fatty liver, fibrosis, or altered hepatic gene expression.
Cystathionine, cysteine, and cystine
Cystathionine can provide information about transsulfuration and vitamin B6-related metabolism.
Cysteine and cystine reflect sulfur amino-acid status and redox conditions, but they are sensitive to handling and oxidation.
A pattern of high methionine, low homocystine, and low cystine may prompt questions about transsulfuration, but it does not establish a diagnosis.
The terms homocysteine and homocystine are also sometimes confused. Clinical total homocysteine is not the same measurement as homocystine on an amino-acid panel.
Interpretation should clarify:
Cysteine and cystine reflect sulfur amino-acid status and redox conditions, but they are sensitive to handling and oxidation.
A pattern of high methionine, low homocystine, and low cystine may prompt questions about transsulfuration, but it does not establish a diagnosis.
The terms homocysteine and homocystine are also sometimes confused. Clinical total homocysteine is not the same measurement as homocystine on an amino-acid panel.
Interpretation should clarify:
- what analyte was actually measured;
- whether the sample was plasma or urine;
- whether the concentration was total or free;
- fasting status;
- sample oxidation and processing;
- vitamin B6 status;
- kidney and liver context.
Choline, betaine, and dimethylglycine
Choline can be used for:
Betaine supports BHMT-dependent remethylation, producing methionine and dimethylglycine.
Potentially informative relationships
Commercial metabolomic panels sometimes assign pathway scores from these metabolites. Such scores are hypotheses, not direct measurements of enzyme activity.
- phosphatidylcholine synthesis;
- acetylcholine synthesis;
- oxidation to betaine.
Betaine supports BHMT-dependent remethylation, producing methionine and dimethylglycine.
Potentially informative relationships
- Low choline intake plus liver fat may raise concern about phosphatidylcholine supply.
- Low betaine with high homocysteine may suggest limited substrate for BHMT, but is not diagnostic.
- Increased dimethylglycine after trimethylglycine can show that betaine is being metabolized, but does not quantify liver benefit.
- High dimethylglycine can reflect intake, BHMT flux, kidney function, or other factors.
Commercial metabolomic panels sometimes assign pathway scores from these metabolites. Such scores are hypotheses, not direct measurements of enzyme activity.
Folate-related markers
Serum folate reflects recent intake more than long-term tissue status. Red-cell folate reflects longer-term exposure but has its own methodological issues.
5-methyltetrahydrofolate is the form used by methionine synthase, but routine testing rarely maps intracellular folate distribution.
A normal or high serum folate does not guarantee normal intracellular vitamin B12-dependent remethylation.
High supplemental folate can coexist with vitamin B12 deficiency. Conversely, a common MTHFR variant does not mean that methylfolate is always required.
5-methyltetrahydrofolate is the form used by methionine synthase, but routine testing rarely maps intracellular folate distribution.
A normal or high serum folate does not guarantee normal intracellular vitamin B12-dependent remethylation.
High supplemental folate can coexist with vitamin B12 deficiency. Conversely, a common MTHFR variant does not mean that methylfolate is always required.
Vitamin B12-related markers
Serum vitamin B12 can be low, normal, or high for multiple reasons.
Methylmalonic acid and holotranscobalamin can add information, but methylmalonic acid rises with kidney dysfunction.
Chronic liver disease can elevate serum vitamin B12 through altered storage, release, and binding proteins.
The useful question is not simply:
“Is vitamin B12 high?”
It is whether the overall evidence supports adequate cellular cobalamin function and whether the result is distorted by liver or kidney disease.
Methylmalonic acid and holotranscobalamin can add information, but methylmalonic acid rises with kidney dysfunction.
Chronic liver disease can elevate serum vitamin B12 through altered storage, release, and binding proteins.
The useful question is not simply:
“Is vitamin B12 high?”
It is whether the overall evidence supports adequate cellular cobalamin function and whether the result is distorted by liver or kidney disease.
Liver enzymes and related tests
Alanine aminotransferase and aspartate aminotransferase
Alanine aminotransferase and aspartate aminotransferase reflect hepatocellular injury, not the liver’s complete functional capacity.
Normal values do not exclude steatosis or fibrosis. Aspartate aminotransferase also comes from muscle and other tissues.
Gamma-glutamyl transferase
Gamma-glutamyl transferase can rise with:
Alkaline phosphatase and bilirubin
These markers help identify cholestatic or biliary patterns. Their interpretation belongs to established liver evaluation, not to a methylation score.
Albumin and coagulation
Albumin and the international normalized ratio contribute information about synthetic function, especially in advanced disease. They may remain normal in early steatosis.
Platelets and fibrosis scores
Platelet count, age, alanine aminotransferase, and aspartate aminotransferase are used in non-invasive fibrosis tools such as the Fibrosis-4 Index.
Fibrosis risk is often more clinically important than a speculative methylation label.
Alanine aminotransferase and aspartate aminotransferase reflect hepatocellular injury, not the liver’s complete functional capacity.
Normal values do not exclude steatosis or fibrosis. Aspartate aminotransferase also comes from muscle and other tissues.
Gamma-glutamyl transferase
Gamma-glutamyl transferase can rise with:
- cholestasis;
- alcohol exposure;
- metabolic liver disease;
- medication.
Alkaline phosphatase and bilirubin
These markers help identify cholestatic or biliary patterns. Their interpretation belongs to established liver evaluation, not to a methylation score.
Albumin and coagulation
Albumin and the international normalized ratio contribute information about synthetic function, especially in advanced disease. They may remain normal in early steatosis.
Platelets and fibrosis scores
Platelet count, age, alanine aminotransferase, and aspartate aminotransferase are used in non-invasive fibrosis tools such as the Fibrosis-4 Index.
Fibrosis risk is often more clinically important than a speculative methylation label.
Imaging and fibrosis assessment
Ultrasound can detect steatosis but has limited sensitivity for mild fat and does not accurately stage fibrosis.
Controlled attenuation parameter, vibration-controlled transient elastography, magnetic resonance-based methods, and other tools can provide additional information. Liver biopsy is reserved for selected situations.
A finding of fatty liver creates a relevant context for methionine and choline metabolism, but it does not establish the direction of SAM change.
Imaging should be interpreted within hepatology guidance.
Controlled attenuation parameter, vibration-controlled transient elastography, magnetic resonance-based methods, and other tools can provide additional information. Liver biopsy is reserved for selected situations.
A finding of fatty liver creates a relevant context for methionine and choline metabolism, but it does not establish the direction of SAM change.
Imaging should be interpreted within hepatology guidance.
Renal markers
Creatinine, estimated glomerular filtration rate, cystatin C, urinary albumin, and the overall renal picture are important when homocysteine, SAM, or SAH are abnormal.
Reduced renal function can increase homocysteine and SAH and may change the SAM/SAH ratio.
A hepatic interpretation that omits kidney function is incomplete.
Reduced renal function can increase homocysteine and SAH and may change the SAM/SAH ratio.
A hepatic interpretation that omits kidney function is incomplete.
Marker combinations and what they may suggest
The following combinations are not diagnoses. They are questions to investigate.
High methionine + high total homocysteine
Consider:
High methionine + normal or low total homocysteine
Consider:
High methionine + low SAM
This pattern could be consistent with constrained methionine-to-SAM conversion, but confirmation and context are essential.
Consider:
High methionine + very high SAM + relatively normal SAH
This is a classic pattern raising concern for GNMT deficiency in the appropriate setting.
It is not a common functional-medicine phenotype.
High methionine + high SAM + very high SAH
Consider:
Low methionine + low SAM
Consider:
Normal methionine + low SAM/SAH ratio
Look at the absolute SAM and SAH values.
Elevated SAH due to kidney dysfunction or impaired clearance may be more important than methionine supply.
Elevated liver enzymes + normal methionine and homocysteine
This does not exclude altered hepatic SAM homeostasis, but the immediate priority is the established differential for liver injury.
Methylation markers are not required to investigate common liver disease.
Fatty liver + low choline intake
This is a plausible nutrient context, especially when intake is clearly inadequate or when a person has been on parenteral nutrition or a highly restrictive diet.
It does not prove that choline is the sole cause of fatty liver.
Fatty liver + PEMT variant
Treat the variant as a modifier.
Assess:
High methionine + high total homocysteine
Consider:
- CBS deficiency, especially if marked or persistent;
- severe vitamin-related or remethylation abnormalities with an unusual context;
- kidney dysfunction;
- liver disease;
- intake or medication effects.
High methionine + normal or low total homocysteine
Consider:
- MAT1A deficiency;
- GNMT deficiency;
- AHCY deficiency;
- adenosine kinase deficiency;
- liver dysfunction;
- recent methionine intake;
- isolated laboratory variation.
High methionine + low SAM
This pattern could be consistent with constrained methionine-to-SAM conversion, but confirmation and context are essential.
Consider:
- MAT1A-related disease;
- acquired reduction in methionine adenosyltransferase activity;
- sample differences;
- the fact that plasma values do not directly measure hepatocyte flux.
High methionine + very high SAM + relatively normal SAH
This is a classic pattern raising concern for GNMT deficiency in the appropriate setting.
It is not a common functional-medicine phenotype.
High methionine + high SAM + very high SAH
Consider:
- AHCY deficiency;
- adenosine kinase deficiency;
- kidney dysfunction;
- severe systemic disease;
- other causes.
Low methionine + low SAM
Consider:
- inadequate intake;
- malabsorption;
- catabolism;
- impaired remethylation;
- reduced methionine adenosyltransferase activity;
- high demand;
- analytical issues.
Normal methionine + low SAM/SAH ratio
Look at the absolute SAM and SAH values.
Elevated SAH due to kidney dysfunction or impaired clearance may be more important than methionine supply.
Elevated liver enzymes + normal methionine and homocysteine
This does not exclude altered hepatic SAM homeostasis, but the immediate priority is the established differential for liver injury.
Methylation markers are not required to investigate common liver disease.
Fatty liver + low choline intake
This is a plausible nutrient context, especially when intake is clearly inadequate or when a person has been on parenteral nutrition or a highly restrictive diet.
It does not prove that choline is the sole cause of fatty liver.
Fatty liver + PEMT variant
Treat the variant as a modifier.
Assess:
- dietary choline;
- metabolic risk;
- sex and hormonal state;
- alcohol;
- medication;
- fibrosis risk.
Similar methylation patterns and how to distinguish them
Methionine-to-SAM Supply Limitation
This narrower pattern focuses on insufficient SAM production from methionine.
Hepatic dysregulation overlaps when MAT1A activity or liver function is the proposed cause. The hepatic pattern is broader because it also includes high SAM, SAH accumulation, altered buffering, and secondary liver contexts.
Key distinction:
Supply limitation asks whether SAM production is inadequate. Hepatic homeostasis asks how the liver is regulating the entire methionine-SAM-SAH system.
SAH-Driven Low Methylation Potential
This pattern focuses on SAH accumulation and methyltransferase inhibition.
It can occur because of:
SAH-driven limitation can be hepatic, renal, inherited, or systemic. The liver pattern is only one possible context.
High SAM-Derived Methyl-Group Demand Pressure
This pattern focuses on high demand for SAM-dependent reactions, including phosphatidylcholine and creatine synthesis.
The hepatic chapter explains why PEMT, GNMT, lipid export, and liver disease can modify that demand.
Key distinction:
High demand is about consumption relative to supply. Hepatic dysregulation can involve high demand, but it can also involve impaired production or impaired use.
Choline-Betaine-Dependent Remethylation Limitation
This pattern focuses on the choline-betaine-BHMT route that remethylates homocysteine to methionine.
The hepatic chapter includes BHMT because the enzyme is highly expressed in the liver and because liver injury can alter its expression.
Key distinction:
BHMT limitation is one branch. Hepatic homeostasis includes SAM synthesis, SAH clearance, GNMT buffering, and PEMT demand as well.
Folate-Limited and Vitamin B12-Dependent Remethylation Patterns
These patterns focus on methionine synthase-dependent recycling of homocysteine.
They can secondarily affect methionine and SAM, but they are not inherently liver-specific.
Key distinction:
A folate or vitamin B12 problem can alter hepatic methionine supply without primary liver dysfunction.
B6-Dependent Transsulfuration Limitation
This pattern focuses on conversion of homocysteine through cystathionine toward cysteine.
It can raise homocysteine and alter glutathione-related supply.
Key distinction:
Transsulfuration is downstream of homocysteine. The hepatic pattern begins earlier and includes both remethylation and SAM regulation.
Accelerated Transsulfuration or Low-Homocysteine Sulfur-Flux Patterns
These interpretations attempt to explain low homocysteine and sulfur-related findings through increased transsulfuration.
Evidence is often indirect.
Key distinction:
Low homocysteine alone does not establish accelerated hepatic transsulfuration. Dietary intake, remethylation, pregnancy, illness, and analytical factors must be considered.
Renal Retention of One-Carbon Metabolites
Renal dysfunction can raise homocysteine, SAH, SAM, and related metabolites, producing a pattern that looks like impaired methylation or liver dysfunction.
Key distinction:
Always review kidney function before assigning abnormal SAM, SAH, or homocysteine to the liver.
This narrower pattern focuses on insufficient SAM production from methionine.
Hepatic dysregulation overlaps when MAT1A activity or liver function is the proposed cause. The hepatic pattern is broader because it also includes high SAM, SAH accumulation, altered buffering, and secondary liver contexts.
Key distinction:
Supply limitation asks whether SAM production is inadequate. Hepatic homeostasis asks how the liver is regulating the entire methionine-SAM-SAH system.
SAH-Driven Low Methylation Potential
This pattern focuses on SAH accumulation and methyltransferase inhibition.
It can occur because of:
- kidney dysfunction;
- altered adenosine metabolism;
- AHCY-related disease;
- high product load;
- liver-related changes.
SAH-driven limitation can be hepatic, renal, inherited, or systemic. The liver pattern is only one possible context.
High SAM-Derived Methyl-Group Demand Pressure
This pattern focuses on high demand for SAM-dependent reactions, including phosphatidylcholine and creatine synthesis.
The hepatic chapter explains why PEMT, GNMT, lipid export, and liver disease can modify that demand.
Key distinction:
High demand is about consumption relative to supply. Hepatic dysregulation can involve high demand, but it can also involve impaired production or impaired use.
Choline-Betaine-Dependent Remethylation Limitation
This pattern focuses on the choline-betaine-BHMT route that remethylates homocysteine to methionine.
The hepatic chapter includes BHMT because the enzyme is highly expressed in the liver and because liver injury can alter its expression.
Key distinction:
BHMT limitation is one branch. Hepatic homeostasis includes SAM synthesis, SAH clearance, GNMT buffering, and PEMT demand as well.
Folate-Limited and Vitamin B12-Dependent Remethylation Patterns
These patterns focus on methionine synthase-dependent recycling of homocysteine.
They can secondarily affect methionine and SAM, but they are not inherently liver-specific.
Key distinction:
A folate or vitamin B12 problem can alter hepatic methionine supply without primary liver dysfunction.
B6-Dependent Transsulfuration Limitation
This pattern focuses on conversion of homocysteine through cystathionine toward cysteine.
It can raise homocysteine and alter glutathione-related supply.
Key distinction:
Transsulfuration is downstream of homocysteine. The hepatic pattern begins earlier and includes both remethylation and SAM regulation.
Accelerated Transsulfuration or Low-Homocysteine Sulfur-Flux Patterns
These interpretations attempt to explain low homocysteine and sulfur-related findings through increased transsulfuration.
Evidence is often indirect.
Key distinction:
Low homocysteine alone does not establish accelerated hepatic transsulfuration. Dietary intake, remethylation, pregnancy, illness, and analytical factors must be considered.
Renal Retention of One-Carbon Metabolites
Renal dysfunction can raise homocysteine, SAH, SAM, and related metabolites, producing a pattern that looks like impaired methylation or liver dysfunction.
Key distinction:
Always review kidney function before assigning abnormal SAM, SAH, or homocysteine to the liver.
A staged interpretation method
Stage 1. Verify the finding
Stage 2. Identify the dominant abnormality
Stage 3. Locate the likely node
Stage 4. Separate common from rare explanations
Common metabolic liver disease, nutritional factors, kidney function, medication, alcohol, and vitamin status should be considered.
The following raise the priority of rare inherited disorders:
Stage 5. Avoid treatment-by-marker
A marker identifies a question, not automatically an intervention.
- Was the test appropriate for the question?
- Was the sample fasting if required?
- Was supplementation stopped or documented?
- Was handling adequate?
- Is the result reproducible?
- Are the units and reference interval clear?
Stage 2. Identify the dominant abnormality
- Is methionine high or low?
- Is SAM high or low?
- Is SAH high?
- Is total homocysteine high or low?
- Are liver injury, cholestatic, or synthetic markers abnormal?
- Is kidney function abnormal?
Stage 3. Locate the likely node
- Methionine supply?
- Methionine adenosyltransferase-dependent SAM production?
- Methyltransferase demand?
- GNMT buffering?
- SAH hydrolysis?
- Homocysteine remethylation?
- Transsulfuration?
- Phosphatidylcholine demand?
- Renal retention?
Stage 4. Separate common from rare explanations
Common metabolic liver disease, nutritional factors, kidney function, medication, alcohol, and vitamin status should be considered.
The following raise the priority of rare inherited disorders:
- marked persistent abnormalities;
- childhood onset;
- neurologic or muscular findings;
- coagulopathy;
- hypoglycemia;
- very high SAM or SAH.
Stage 5. Avoid treatment-by-marker
A marker identifies a question, not automatically an intervention.
- High homocysteine does not always mean methylfolate.
- Low SAM does not always mean SAMe.
- High methionine does not always mean protein restriction.
- A low SAM/SAH ratio does not always mean more methyl donors.
Diet and Supplement Responses
Understand what reactions to methionine, SAMe, choline, TMG, protein, and methyl donors may and may not mean
This block addresses the questions that most often lead people into the topic.
It does not provide a supplement protocol.
Its purpose is to explain why a response can be real without proving the proposed mechanism.
A response to food or a supplement is shaped by dose, timing, formulation, baseline nutrient status, medications, sleep, gastrointestinal absorption, kidney function, liver disease, genetic disease, expectation, and simultaneous changes.
The same substance can help at one dose and cause problems at another. It can also produce different effects on different days.
It does not provide a supplement protocol.
Its purpose is to explain why a response can be real without proving the proposed mechanism.
A response to food or a supplement is shaped by dose, timing, formulation, baseline nutrient status, medications, sleep, gastrointestinal absorption, kidney function, liver disease, genetic disease, expectation, and simultaneous changes.
The same substance can help at one dose and cause problems at another. It can also produce different effects on different days.
S-adenosylmethionine supplementation
S-adenosylmethionine is sold as SAMe.
Oral SAMe has been studied in depression, osteoarthritis, cholestatic conditions, and liver disease. It is pharmacologically active and is not simply a nutritional equivalent of eating methionine.
Why it may help
Possible reasons include:
SAMe acts in multiple tissues.
Why it may cause activation, anxiety, or insomnia
Possible contributors include:
It is a reason to reconsider dose, safety, interactions, and whether the compound is appropriate.
Why the effect may fade
An initial response can diminish because of adaptation, changing expectations, altered sleep, progression of the underlying condition, inadequate adherence, formulation differences, or because the original effect was not caused by a persistent SAM deficiency. A fading response does not prove depletion of another cofactor.
Why stopping can feel difficult
Some users report a return of low mood or energy after stopping. This may represent recurrence of the underlying symptoms, an adjustment effect, or expectation. Evidence for a defined SAMe withdrawal syndrome is limited. Persistent or severe changes should be evaluated rather than managed through escalating self-experimentation.
Medication safety
SAMe can interact with serotonergic medication and may contribute to serotonin-related adverse effects. It may also provoke mania or hypomania in susceptible individuals. Pregnancy, bipolar disorder, significant medical illness, and complex medication regimens require professional guidance.
Liver evidence
The liver rationale is strong, but clinical trials are mixed. Some studies suggest biochemical or symptom improvement in selected cholestatic or chronic liver conditions. Trials in alcohol-related liver disease have not produced consistently positive outcomes. SAMe should not be presented as a general treatment for fatty liver or elevated liver enzymes.
Oral SAMe has been studied in depression, osteoarthritis, cholestatic conditions, and liver disease. It is pharmacologically active and is not simply a nutritional equivalent of eating methionine.
Why it may help
Possible reasons include:
- bypassing a constrained methionine-to-SAM step;
- influencing monoamine-related methylation and neurotransmitter metabolism;
- supporting selected phospholipid or glutathione-related pathways;
- pharmacologic effects unrelated to a documented deficiency;
- correction of a true low-SAM state in a specific disease context.
SAMe acts in multiple tissues.
Why it may cause activation, anxiety, or insomnia
Possible contributors include:
- dose too high for the individual;
- rapid changes in neurotransmitter-related pathways;
- bipolar-spectrum vulnerability or mood activation;
- interaction with antidepressants or other serotonergic agents;
- timing late in the day;
- gastrointestinal effects or sleep disruption;
- downstream demand for cofactors and substrates;
- expectation and concurrent changes.
It is a reason to reconsider dose, safety, interactions, and whether the compound is appropriate.
Why the effect may fade
An initial response can diminish because of adaptation, changing expectations, altered sleep, progression of the underlying condition, inadequate adherence, formulation differences, or because the original effect was not caused by a persistent SAM deficiency. A fading response does not prove depletion of another cofactor.
Why stopping can feel difficult
Some users report a return of low mood or energy after stopping. This may represent recurrence of the underlying symptoms, an adjustment effect, or expectation. Evidence for a defined SAMe withdrawal syndrome is limited. Persistent or severe changes should be evaluated rather than managed through escalating self-experimentation.
Medication safety
SAMe can interact with serotonergic medication and may contribute to serotonin-related adverse effects. It may also provoke mania or hypomania in susceptible individuals. Pregnancy, bipolar disorder, significant medical illness, and complex medication regimens require professional guidance.
Liver evidence
The liver rationale is strong, but clinical trials are mixed. Some studies suggest biochemical or symptom improvement in selected cholestatic or chronic liver conditions. Trials in alcohol-related liver disease have not produced consistently positive outcomes. SAMe should not be presented as a general treatment for fatty liver or elevated liver enzymes.
L-methionine supplementation
L-methionine is an essential amino acid, but isolated supplementation changes the pathway differently from SAMe.
Why someone considers it
What it can and cannot show
If methionine improves a symptom, that may indicate substrate responsiveness, but it does not prove hepatic MAT activity is normal or abnormal. If it worsens anxiety, insomnia, nausea, or sulfur-related symptoms, the response does not diagnose high SAM or CBS upregulation.
Main caution
Methionine should not be added casually when methionine is already high, when the cause of a low value is unknown, or when an inherited disorder is possible. Marked hypermethioninemia can have neurologic consequences in selected disorders. The essential status of methionine does not make high-dose isolated supplementation universally safe.
Why someone considers it
- low methionine on an amino-acid panel;
- low-protein or plant-based diet concerns;
- a theory that SAM production is substrate-limited;
- attempts to raise homocysteine;
- mood or detoxification claims.
What it can and cannot show
If methionine improves a symptom, that may indicate substrate responsiveness, but it does not prove hepatic MAT activity is normal or abnormal. If it worsens anxiety, insomnia, nausea, or sulfur-related symptoms, the response does not diagnose high SAM or CBS upregulation.
Main caution
Methionine should not be added casually when methionine is already high, when the cause of a low value is unknown, or when an inherited disorder is possible. Marked hypermethioninemia can have neurologic consequences in selected disorders. The essential status of methionine does not make high-dose isolated supplementation universally safe.
Protein-rich foods and protein supplements
People sometimes report feeling worse after high-protein meals and attribute the reaction to methionine or slow COMT.
Protein meals also change blood glucose, insulin, glucagon, gut hormones, ammonia production, large neutral amino-acid competition, gastrointestinal load, and hydration. Protein powders may include sweeteners, additives, dairy proteins, histamine-related ingredients, or contaminants.
What a response does not prove
What to investigate instead
In advanced cirrhosis, protein recommendations require individualized clinical nutrition. Older advice to broadly restrict protein has largely been replaced by efforts to prevent malnutrition and sarcopenia, except in selected circumstances. Self-imposed restriction can be harmful.
Protein meals also change blood glucose, insulin, glucagon, gut hormones, ammonia production, large neutral amino-acid competition, gastrointestinal load, and hydration. Protein powders may include sweeteners, additives, dairy proteins, histamine-related ingredients, or contaminants.
What a response does not prove
- that methionine is accumulating;
- that COMT is overwhelmed by methyl groups;
- that the liver cannot process protein;
- that a low-protein diet is required;
- that the person has an inherited methylation disorder.
What to investigate instead
- total amount and meal size;
- source of protein;
- carbohydrate and fat context;
- digestive symptoms;
- kidney and liver status;
- ammonia-related concerns in advanced liver disease;
- overall energy intake;
- actual plasma amino-acid results if clinically indicated.
In advanced cirrhosis, protein recommendations require individualized clinical nutrition. Older advice to broadly restrict protein has largely been replaced by efforts to prevent malnutrition and sarcopenia, except in selected circumstances. Self-imposed restriction can be harmful.
Choline
Choline supplements come in several forms, including choline salts, phosphatidylcholine, citicoline, and alpha-glycerylphosphorylcholine. These forms differ in pharmacology and cannot be treated as interchangeable.
Why choline may help
Why choline may cause adverse effects
A cognitive response to citicoline or alpha-glycerylphosphorylcholine does not demonstrate that hepatic phosphatidylcholine synthesis was deficient. These compounds have central nervous system effects.
Fatty liver and choline
Human depletion studies show that choline deficiency can cause fatty liver in susceptible people and that repletion can reverse the induced abnormality. This is strong evidence for deficiency-related steatosis. It is not evidence that most metabolic dysfunction-associated steatotic liver disease can be treated with choline alone.
Genotype-guided dosing
No common phosphatidylethanolamine N-methyltransferase (PEMT) variant currently provides a validated personal dose. Intake assessment, food sources, hormonal state, tolerability, metabolic risk, and liver evaluation are more informative than a single variant.
Why choline may help
- correction of low dietary intake;
- support of phosphatidylcholine synthesis;
- support of acetylcholine-related function;
- increased betaine production through oxidation;
- selected parenteral-nutrition or deficiency contexts.
Why choline may cause adverse effects
- gastrointestinal discomfort;
- fishy body odor at high intake due to trimethylamine;
- sweating or salivation;
- headache or mood changes;
- cholinergic effects depending on form;
- interaction with gut microbial metabolism;
- dose or formulation intolerance.
A cognitive response to citicoline or alpha-glycerylphosphorylcholine does not demonstrate that hepatic phosphatidylcholine synthesis was deficient. These compounds have central nervous system effects.
Fatty liver and choline
Human depletion studies show that choline deficiency can cause fatty liver in susceptible people and that repletion can reverse the induced abnormality. This is strong evidence for deficiency-related steatosis. It is not evidence that most metabolic dysfunction-associated steatotic liver disease can be treated with choline alone.
Genotype-guided dosing
No common phosphatidylethanolamine N-methyltransferase (PEMT) variant currently provides a validated personal dose. Intake assessment, food sources, hormonal state, tolerability, metabolic risk, and liver evaluation are more informative than a single variant.
Phosphatidylcholine
Phosphatidylcholine directly supplies a major phospholipid and differs from free choline. It is used in cell membranes, bile, and lipoproteins.
Oral phosphatidylcholine is digested and remodeled, so it does not simply travel intact to a deficient hepatic pool.
Improvement in digestive tolerance or cognition after phosphatidylcholine does not prove PEMT insufficiency.
Lack of response does not prove adequate choline status. Products vary in purity and phospholipid composition.
Oral phosphatidylcholine is digested and remodeled, so it does not simply travel intact to a deficient hepatic pool.
Improvement in digestive tolerance or cognition after phosphatidylcholine does not prove PEMT insufficiency.
Lack of response does not prove adequate choline status. Products vary in purity and phospholipid composition.
Trimethylglycine and betaine
Trimethylglycine is betaine. Through betaine-homocysteine methyltransferase (BHMT), it donates a methyl group to homocysteine, producing methionine and dimethylglycine.
It is sometimes used to lower homocysteine and is an established therapy component in selected inherited homocystinurias under medical supervision.
Why responses vary
Why TMG can feel stimulating or sedating
The subjective effect may involve downstream methionine and SAM, changes in homocysteine, osmolyte effects, other supplements, sleep, or expectation. There is no validated rule that stimulation equals overmethylation and sedation equals undermethylation.
The important caution
Lowering homocysteine is not the only outcome. Betaine can raise methionine, which matters in certain inherited disorders. Treatment of homocystinuria uses monitoring and diagnosis, not indiscriminate dosing.
It is sometimes used to lower homocysteine and is an established therapy component in selected inherited homocystinurias under medical supervision.
Why responses vary
- baseline homocysteine may be low, normal, or high;
- BHMT activity and liver expression vary;
- folate-dependent remethylation may be adequate or constrained;
- methionine and SAM may already be high;
- dose can affect gastrointestinal tolerance;
- betaine can influence osmolyte balance and lipid metabolism;
- concurrent methylfolate, vitamin B12, choline, and SAMe alter the context.
Why TMG can feel stimulating or sedating
The subjective effect may involve downstream methionine and SAM, changes in homocysteine, osmolyte effects, other supplements, sleep, or expectation. There is no validated rule that stimulation equals overmethylation and sedation equals undermethylation.
The important caution
Lowering homocysteine is not the only outcome. Betaine can raise methionine, which matters in certain inherited disorders. Treatment of homocystinuria uses monitoring and diagnosis, not indiscriminate dosing.
Methylfolate
Methylfolate can support methionine synthase-dependent remethylation when folate supply or methylenetetrahydrofolate reductase-related conversion is limiting. It can also produce strong subjective effects in some people.
Commonly reported pattern
A person feels clearer or more energetic for several days, then develops anxiety, insomnia, headache, irritability, or a “crash.” Several explanations are possible:
The reaction does not prove a liver bottleneck or the need to add every downstream cofactor.
Liver context
Chronic liver disease can alter folate status, but methylfolate is not a treatment for liver disease. High folate intake can mask hematologic signs of vitamin B12 deficiency, so vitamin B12 context matters.
Commonly reported pattern
A person feels clearer or more energetic for several days, then develops anxiety, insomnia, headache, irritability, or a “crash.” Several explanations are possible:
- dose exceeds current tolerance;
- vitamin B12 status is inadequate;
- the original response was pharmacologic rather than correction of deficiency;
- sleep loss accumulates;
- other supplements create combined stimulation;
- an unrelated condition is fluctuating;
- expectation amplifies interpretation.
The reaction does not prove a liver bottleneck or the need to add every downstream cofactor.
Liver context
Chronic liver disease can alter folate status, but methylfolate is not a treatment for liver disease. High folate intake can mask hematologic signs of vitamin B12 deficiency, so vitamin B12 context matters.
Methylcobalamin and other vitamin B12 forms
Methylcobalamin provides a cofactor form used by methionine synthase. Adenosylcobalamin supports methylmalonyl-coenzyme A mutase.
Hydroxocobalamin can be converted to active forms and is used in several clinical contexts.
A response to one form does not reveal a universal “COMT type.”
High serum vitamin B12 after supplementation is expected and does not measure intracellular methylation.
Unexpectedly high serum vitamin B12 without supplementation can occur in liver disease, hematologic disease, kidney disease, or other conditions and should not be dismissed as “excellent status.”
Hydroxocobalamin can be converted to active forms and is used in several clinical contexts.
A response to one form does not reveal a universal “COMT type.”
High serum vitamin B12 after supplementation is expected and does not measure intracellular methylation.
Unexpectedly high serum vitamin B12 without supplementation can occur in liver disease, hematologic disease, kidney disease, or other conditions and should not be dismissed as “excellent status.”
Glycine
Glycine is a substrate for glycine N-methyltransferase (GNMT) and glutathione synthesis and participates in many other pathways.
Why people use it
Why the interpretation is difficult
Glycine can have inhibitory neurotransmitter effects in some regions and excitatory co-agonist effects at N-methyl-D-aspartate receptors in others.
It also affects metabolism and temperature regulation. A calming response does not prove excess SAM, and an activating response does not prove GNMT dysfunction.
In true GNMT deficiency, adding glycine cannot replace the missing enzyme activity. In common metabolic contexts, the effect of glycine on hepatic SAM buffering in humans is not established as a diagnostic intervention.
Why people use it
- to support sleep;
- to buffer perceived excess methyl groups;
- to support glutathione;
- to balance high methionine intake;
- to support collagen.
Why the interpretation is difficult
Glycine can have inhibitory neurotransmitter effects in some regions and excitatory co-agonist effects at N-methyl-D-aspartate receptors in others.
It also affects metabolism and temperature regulation. A calming response does not prove excess SAM, and an activating response does not prove GNMT dysfunction.
In true GNMT deficiency, adding glycine cannot replace the missing enzyme activity. In common metabolic contexts, the effect of glycine on hepatic SAM buffering in humans is not established as a diagnostic intervention.
Creatine
Creatine may reduce endogenous guanidinoacetate methylation and thereby spare SAM-dependent methyl demand.
It also directly supports muscle phosphocreatine and can affect strength, cognition, and water retention.
A beneficial response may arise from muscle or brain energy effects rather than methyl-group sparing.
Irritability, gastrointestinal symptoms, or sleep changes are not specific to methylation. Kidney function and the interpretation of creatinine should be considered.
It also directly supports muscle phosphocreatine and can affect strength, cognition, and water retention.
A beneficial response may arise from muscle or brain energy effects rather than methyl-group sparing.
Irritability, gastrointestinal symptoms, or sleep changes are not specific to methylation. Kidney function and the interpretation of creatinine should be considered.
N-acetylcysteine
N-acetylcysteine supplies cysteine and has antioxidant and mucolytic effects. It is used medically in acetaminophen toxicity and other selected settings.
Why it enters methylation discussions
It connects to cysteine and glutathione downstream of transsulfuration. People may use it when they believe homocysteine is being diverted too slowly or when oxidative stress is high.
Why responses vary
N-acetylcysteine can affect glutamate-related signaling, histamine-related symptoms, gastrointestinal function, and redox state. A paradoxical reaction does not prove sulfur intolerance or hepatic transsulfuration overload.
In acute or chronic liver concerns, N-acetylcysteine should not be used as a substitute for identifying the cause of injury.
Why it enters methylation discussions
It connects to cysteine and glutathione downstream of transsulfuration. People may use it when they believe homocysteine is being diverted too slowly or when oxidative stress is high.
Why responses vary
N-acetylcysteine can affect glutamate-related signaling, histamine-related symptoms, gastrointestinal function, and redox state. A paradoxical reaction does not prove sulfur intolerance or hepatic transsulfuration overload.
In acute or chronic liver concerns, N-acetylcysteine should not be used as a substitute for identifying the cause of injury.
Niacin and “methyl-group draining”
Niacin metabolism can use methyl groups, and niacin is sometimes recommended online to stop methyl-donor reactions.
This is an oversimplified and potentially unsafe practice.
Niacin has dose-dependent effects on flushing, glucose, uric acid, and the liver. Sustained-release high-dose products can cause hepatotoxicity.
Using niacin as an antidote to an undefined “overmethylation” state can add liver risk to an already confusing situation.
This is an oversimplified and potentially unsafe practice.
Niacin has dose-dependent effects on flushing, glucose, uric acid, and the liver. Sustained-release high-dose products can cause hepatotoxicity.
Using niacin as an antidote to an undefined “overmethylation” state can add liver risk to an already confusing situation.
Magnesium and other cofactors
Adenosine triphosphate-dependent reactions require magnesium, and many enzymes in one-carbon metabolism depend directly or indirectly on micronutrients.
Yet normal biochemical dependence does not mean that magnesium deficiency is the cause of every SAMe response.
Supplement combinations often make interpretation impossible. A person may begin methylfolate, vitamin B12, trimethylglycine, magnesium, choline, creatine, and glycine within one week. When symptoms change, no individual cause can be identified.
Yet normal biochemical dependence does not mean that magnesium deficiency is the cause of every SAMe response.
Supplement combinations often make interpretation impossible. A person may begin methylfolate, vitamin B12, trimethylglycine, magnesium, choline, creatine, and glycine within one week. When symptoms change, no individual cause can be identified.
The one-change principle
For educational self-navigation, the safest interpretive principle is not a dosing protocol but an observation rule:
Change one nonessential variable at a time, use the lowest reasonable exposure, define what is being observed, and stop interpreting subjective effects as proof of enzyme activity.
This principle does not apply when a clinician has prescribed treatment for a diagnosed deficiency or inherited disorder. It applies to self-directed experimentation in uncertain contexts.
How to read a positive response
A positive response may mean:
How to read a negative response
A negative response may mean:
Change one nonessential variable at a time, use the lowest reasonable exposure, define what is being observed, and stop interpreting subjective effects as proof of enzyme activity.
This principle does not apply when a clinician has prescribed treatment for a diagnosed deficiency or inherited disorder. It applies to self-directed experimentation in uncertain contexts.
How to read a positive response
A positive response may mean:
- the person was deficient or had inadequate intake;
- the compound bypassed a constrained step;
- the compound had a pharmacologic effect;
- another pathway was affected;
- the dose altered sleep, energy, or expectation;
- the underlying condition naturally fluctuated.
How to read a negative response
A negative response may mean:
- the dose was too high;
- the formulation was unsuitable;
- the compound interacted with medication;
- the proposed pathway was not the main problem;
- the timing was poor;
- the person has a condition in which the supplement is inappropriate;
- the symptom was unrelated.
Case-based evidence from human studies
Controlled choline depletion and repletion
In controlled feeding studies, participants consumed diets with adequate choline and were then placed on low-choline diets. A subset developed increased liver fat, aminotransferase elevation, or muscle injury.
Abnormalities improved with choline repletion. Genetic variation and sex or menopausal status modified susceptibility.
What this supports:
SAMe in alcoholic cirrhosis
A randomized two-year trial in 123 patients with alcoholic cirrhosis reported a possible benefit in survival or transplantation-free outcome, particularly in less advanced disease, but interpretation was influenced by subgroup analysis. A later 24-week randomized trial in 37 abstinent patients found no advantage of SAMe over placebo, while abstinence itself improved liver function.
What this supports:
Rare methylation disorders treated with methionine restriction
Published cases of S-adenosylhomocysteine hydrolase deficiency and adenosine kinase deficiency describe methionine restriction under specialist management, with biochemical improvement and variable clinical response.
What this supports:
What this does not support:
In controlled feeding studies, participants consumed diets with adequate choline and were then placed on low-choline diets. A subset developed increased liver fat, aminotransferase elevation, or muscle injury.
Abnormalities improved with choline repletion. Genetic variation and sex or menopausal status modified susceptibility.
What this supports:
- human choline requirements vary;
- deficiency can cause liver fat and injury;
- repletion can reverse deficiency-induced abnormalities.
- diagnosing choline deficiency from any fatty liver finding;
- assuming a PEMT variant is causal;
- using high-dose choline without assessing total context.
SAMe in alcoholic cirrhosis
A randomized two-year trial in 123 patients with alcoholic cirrhosis reported a possible benefit in survival or transplantation-free outcome, particularly in less advanced disease, but interpretation was influenced by subgroup analysis. A later 24-week randomized trial in 37 abstinent patients found no advantage of SAMe over placebo, while abstinence itself improved liver function.
What this supports:
- biologic plausibility alone does not guarantee a consistent clinical effect;
- disease stage and primary-cause control matter;
- SAMe evidence is condition-specific and mixed.
Rare methylation disorders treated with methionine restriction
Published cases of S-adenosylhomocysteine hydrolase deficiency and adenosine kinase deficiency describe methionine restriction under specialist management, with biochemical improvement and variable clinical response.
What this supports:
- dietary methionine can be therapeutically manipulated in specific diagnosed disorders;
- monitoring SAM, SAH, methionine, growth, nutrition, and clinical status is essential.
What this does not support:
- applying severe methionine restriction to common fatigue, fatty liver, or supplement sensitivity;
- inferring a rare disorder from a common single-nucleotide polymorphism.
When supplement experimentation obscures the real problem
A pattern becomes harder to interpret when:
- multiple methyl donors are taken together;
- doses change every few days;
- liver enzymes are not rechecked after a suspected supplement injury;
- alcohol, medication, sleep apnea, metabolic disease, or thyroid dysfunction are not addressed;
- a person restricts protein despite weight loss or sarcopenia;
- a commercial algorithm is treated as more authoritative than standard clinical findings.
Evidence, Safety, and Takeaways
Separate established biochemistry from individual interpretation
Hepatic methionine and S-adenosylmethionine (SAM) metabolism is supported by well-established biochemistry.
The liver plays a major role in converting methionine into SAM, using SAM in methyltransferase reactions, clearing S-adenosylhomocysteine (SAH), remethylating homocysteine, supporting transsulfuration, and producing phosphatidylcholine.
It is also well established that different disturbances can produce different biochemical patterns. Reduced SAM production, SAH accumulation, impaired SAM buffering, persistent hypermethioninemia, and mixed changes in chronic liver disease should not be treated as one uniform state of “low” or “high” methylation.
The strongest evidence supports:
Evidence for supplements is more condition-specific.
SAMe, choline, betaine, methionine, methylfolate, glycine, and creatine may affect connected pathways, but a plausible biochemical mechanism does not establish that a supplement will be effective or appropriate for a particular person.
What the evidence does not support:
Current evidence does not support diagnosing hepatic methionine or SAM dysregulation from:
Essential safety guardrails
Persistent or marked hypermethioninemia should not be managed through unsupervised protein restriction or supplement trials. It may require evaluation for liver disease or an inherited metabolic disorder.
Kidney function should be considered whenever homocysteine, SAM, SAH, methylmalonic acid, or related metabolites are abnormal.
Normal aminotransferases do not exclude fatty liver or fibrosis. Standard liver assessment remains more important than speculative methylation interpretation.
More methyl donors are not automatically helpful. High SAH, impaired SAM buffering, renal dysfunction, or persistent hypermethioninemia may require a different interpretation from simple methyl-donor deficiency.
Common genetic variants are usually modifiers, not diagnoses. They do not directly measure enzyme activity or determine supplement requirements.
Severe methionine or protein restriction can cause nutritional harm. Therapeutic restriction is reserved for specific diagnosed disorders and requires professional monitoring.
The liver plays a major role in converting methionine into SAM, using SAM in methyltransferase reactions, clearing S-adenosylhomocysteine (SAH), remethylating homocysteine, supporting transsulfuration, and producing phosphatidylcholine.
It is also well established that different disturbances can produce different biochemical patterns. Reduced SAM production, SAH accumulation, impaired SAM buffering, persistent hypermethioninemia, and mixed changes in chronic liver disease should not be treated as one uniform state of “low” or “high” methylation.
The strongest evidence supports:
- the central roles of MAT1A, MAT2A, GNMT, AHCY, BHMT, and PEMT in hepatic methionine and SAM metabolism;
- altered methionine-cycle regulation in chronic liver disease;
- recognized inherited disorders involving MAT1A, GNMT, AHCY, and ADK;
- the ability of choline deficiency to cause liver fat and liver or muscle injury in susceptible people;
- the importance of interpreting liver, kidney, nutritional, and metabolic context together.
Evidence for supplements is more condition-specific.
SAMe, choline, betaine, methionine, methylfolate, glycine, and creatine may affect connected pathways, but a plausible biochemical mechanism does not establish that a supplement will be effective or appropriate for a particular person.
What the evidence does not support:
Current evidence does not support diagnosing hepatic methionine or SAM dysregulation from:
- fatigue, anxiety, brain fog, or another nonspecific symptom;
- one common genetic variant;
- one isolated metabolite;
- a commercial methylation score;
- improvement or worsening after a methyl donor;
- labels such as “overmethylation” or “undermethylation.”
Essential safety guardrails
Persistent or marked hypermethioninemia should not be managed through unsupervised protein restriction or supplement trials. It may require evaluation for liver disease or an inherited metabolic disorder.
Kidney function should be considered whenever homocysteine, SAM, SAH, methylmalonic acid, or related metabolites are abnormal.
Normal aminotransferases do not exclude fatty liver or fibrosis. Standard liver assessment remains more important than speculative methylation interpretation.
More methyl donors are not automatically helpful. High SAH, impaired SAM buffering, renal dysfunction, or persistent hypermethioninemia may require a different interpretation from simple methyl-donor deficiency.
Common genetic variants are usually modifiers, not diagnoses. They do not directly measure enzyme activity or determine supplement requirements.
Severe methionine or protein restriction can cause nutritional harm. Therapeutic restriction is reserved for specific diagnosed disorders and requires professional monitoring.
Takeaway
Hepatic Methionine Metabolism and SAM Homeostasis Dysregulation is best understood as a family of liver-related biochemical disturbances rather than a single state of high or low methylation.
The pattern can involve:
It begins with the exact finding, verifies technical quality, considers standard liver and renal explanations, distinguishes common from rare causes, and identifies the most plausible pathway node. It does not begin with a global label.
A person can have high methionine and low SAM. Another can have high methionine and very high SAM. A third can have normal SAM but elevated SAH. A fourth can have fatty liver with normal routine methylation markers. These are not contradictory versions of one simple condition. They are different biochemical situations that require different questions.
The responsible conclusion is therefore not that liver-related methylation changes are too complex to be useful. The responsible conclusion is that their usefulness depends on precision.
A response is information. A marker is a clue. A pathway model is a hypothesis. None of them, alone, is a diagnosis.
The pattern can involve:
- insufficient conversion of methionine into SAM;
- excessive or poorly buffered SAM;
- accumulation of SAH;
- altered remethylation through folate, vitamin B12, choline, or betaine pathways;
- increased or redistributed SAM demand;
- disturbed phosphatidylcholine synthesis and lipid export;
- altered transsulfuration and glutathione-related metabolism;
- secondary changes caused by liver disease, kidney dysfunction, nutrition, alcohol, medication, or systemic illness.
It begins with the exact finding, verifies technical quality, considers standard liver and renal explanations, distinguishes common from rare causes, and identifies the most plausible pathway node. It does not begin with a global label.
A person can have high methionine and low SAM. Another can have high methionine and very high SAM. A third can have normal SAM but elevated SAH. A fourth can have fatty liver with normal routine methylation markers. These are not contradictory versions of one simple condition. They are different biochemical situations that require different questions.
The responsible conclusion is therefore not that liver-related methylation changes are too complex to be useful. The responsible conclusion is that their usefulness depends on precision.
A response is information. A marker is a clue. A pathway model is a hypothesis. None of them, alone, is a diagnosis.
Evidence map and source roles
Core Hepatic Methionine and SAM Biology
1. Mato JM, Martínez-Chantar ML, Lu SC. S-adenosylmethionine metabolism and liver disease. Annals of Hepatology. 2013. Grade B. Comprehensive mechanistic review integrating human liver disease and experimental evidence.
2. Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiological Reviews. 2012. Grade B. Authoritative review of MAT1A, MAT2A, GNMT, SAM homeostasis, liver injury, and carcinogenesis.
3. Ramani K, Lu SC. Methionine adenosyltransferases in liver health and diseases. Liver Research. 2017. Grade B. Review of methionine adenosyltransferase isoforms, the MAT1A/MAT2A switch, fibrosis, and cancer biology.
4. Li Z, Wang F, Liang B, Su Y, Sun S, Xia S, et al. Methionine metabolism in chronic liver diseases: an update on molecular mechanism and therapeutic implication. Signal Transduction and Targeted Therapy. 2020. Grade B. Detailed review of methionine-cycle remodeling across chronic liver diseases.
5. Frau M, Feo F, Pascale RM. Pleiotropic effects of methionine adenosyltransferases deregulation in liver cancer. International Journal of Molecular Sciences. 2013. Grade C. Mechanistic and translational evidence on methionine adenosyltransferase dysregulation in hepatocarcinogenesis.
6. Ji Y, Nordgren KK, Chai Y, Hebbring SJ, Jenkins GD, Abo RP, et al. Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and genotype-phenotype correlation. Drug Metabolism and Disposition. 2012. Grade B. Human genetic and functional study of MAT1A and GNMT variation.
Inherited Methylation Disorders
7. Barić I, Staufner C, Augoustides-Savvopoulou P, Chien YH, Dobbelaere D, Grünert SC, et al. Consensus recommendations for the diagnosis, treatment and follow-up of inherited methylation disorders. Journal of Inherited Metabolic Disease. 2017. Grade A. Formal consensus covering methionine adenosyltransferase I/III, GNMT, AHCY, and adenosine kinase deficiencies.
8. Chamberlin ME, Ubagai T, Mudd SH, Wilson WG, Leonard JV, Chou JY. Methionine adenosyltransferase I/III deficiency: novel mutations and clinical variations. American Journal of Human Genetics. 2000. Grade C. Human case series and molecular characterization.
9. Chien YH, Abdenur JE, Baronio F, Bannick AA, Corrales F, Couce M, et al. Mudd's disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotes. Orphanet Journal of Rare Diseases. 2015. Grade B/C. Multicenter rare-disease survey with genotype and phenotype data.
10. Barić I, Fumić K, Glenn B, Cuk M, Schulze A, Finkelstein JD, et al. S-adenosylhomocysteine hydrolase deficiency in a human: a genetic disorder of methionine metabolism. Proceedings of the National Academy of Sciences. 2004. Grade C. Foundational human case and biochemical characterization.
11. Buist NRM, Glenn B, Vugrek O, Wagner C, Stabler S, Allen RH, et al. S-adenosylhomocysteine hydrolase deficiency in a 26-year-old man. Journal of Inherited Metabolic Disease. 2006. Grade C. Adult case demonstrating long-term multisystem expression.
12. Huang Y, et al. The biochemical profile and dietary management in S-adenosylhomocysteine hydrolase deficiency. Molecular Genetics and Metabolism Reports. 2022. Grade C. Case report plus synthesis of reported biochemical patterns.
13. Almuhsen N, et al. Clinical utility of methionine restriction in adenosine kinase deficiency. JIMD Reports. 2021. Grade C. Case-based evidence on dietary management in a rare disorder.
14. Barić I, et al. Glycine N-methyltransferase deficiency: a member of the expanding family of inherited disorders of methylation. Molecular Genetics and Metabolism. 2016. Grade C. Rare-disease review and patient evidence.
Liver-Disease Guidance and Clinical Context
15. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023. Grade A. Standard clinical assessment, fibrosis risk stratification, and management guidance.
16. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease. Journal of Hepatology. 2024. Grade A. Current European MASLD guidance.
17. Tang Y, et al. Association of serum methionine metabolites with non-alcoholic fatty liver disease. Nutrition and Metabolism. 2022. Grade B. Human observational evidence for altered circulating SAM, SAH, and homocysteine in fatty liver.
18. Piras IS, et al. Hepatic PEMT expression decreases with increasing severity of NAFLD in obese individuals and postmenopausal women. International Journal of Molecular Sciences. 2022. Grade B. Human liver-tissue study linking PEMT expression with disease severity.
19. Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A, et al. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. American Journal of Clinical Nutrition. 2012. Grade B. Human cohort examining choline intake and histologic severity.
Choline, PEMT, and Controlled Human Evidence
20. da Costa KA, Kozyreva OG, Song J, Galanko JA, Fischer LM, Zeisel SH. Common genetic polymorphisms affect the human requirement for the nutrient choline. FASEB Journal. 2006. Grade A/B. Controlled human depletion-repletion study with genetic modifiers.
21. Sha W, da Costa KA, Fischer LM, Milburn MV, Lawton KA, Berger A, et al. Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline. FASEB Journal. 2010. Grade A/B. Controlled human feeding study with objective liver outcomes.
22. Mehedint MG, Zeisel SH. Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. Current Opinion in Clinical Nutrition and Metabolic Care. 2013. Grade B. Review centered on human depletion studies and hepatic mechanisms.
23. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Current Opinion in Gastroenterology. 2012. Grade B. Integrative review of choline, PEMT, very-low-density lipoprotein export, and fatty liver.
24. Li J, et al. Phosphatidylethanolamine N-methyltransferase: from functions to diseases. Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids. 2023. Grade B/C. Mechanistic review of PEMT and phosphatidylcholine biology.
25. Obeid R, et al. Choline: a scoping review for Nordic Nutrition Recommendations 2023. Food and Nutrition Research. 2023. Grade A/B. Evidence synthesis on choline requirements and health outcomes.
SAMe Intervention Evidence
26. Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Journal of Hepatology. 1999. Grade A/B. Long-term randomized trial with subgroup-dependent findings.
27. Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF, et al. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research. 2011. Grade A. Randomized trial finding no added benefit over placebo during abstinence.
28. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database of Systematic Reviews. 2001. Grade A. Systematic review emphasizing limited and heterogeneous evidence.
29. Guo T, Chang L, Xiao Y, Liu Q. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS One. 2015. Grade A/B. Evidence synthesis across heterogeneous liver conditions.
30. Noureddin M, et al. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: a systematic review. World Journal of Hepatology. 2020. Grade A/B. Review of biochemical and symptom outcomes in cholestasis.
31. Baden KER, et al. S-Adenosylmethionine for liver health: a systematic review. Nutrients. 2024. Grade A/B. Recent systematic review, interpreted cautiously because included conditions and outcomes are heterogeneous.
Measurement and Interpretation
32. Adaikalakoteswari A, et al. Simultaneous detection of five one-carbon metabolites in plasma by liquid chromatography-tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine. 2016. Grade B. Analytical study of SAM, SAH, methionine, homocysteine, and methylmalonic acid measurement.
33. Bravo AC, et al. Method optimisation and profiling of S-adenosylmethionine and S-adenosylhomocysteine in healthy adults. Nutrients. 2022. Grade B. Methodological and reference-profile evidence.
34. Klepacki J, Brunner N, Schmitz V, Klawitter J, Christians U. Development and validation of an LC-MS/MS assay for the determination of SAM and SAH in human plasma. Journal of Chromatography B. 2013. Grade B. Analytical validation and discussion of clinical confounders.
35. Hao X, et al. Immunoassay of S-adenosylmethionine and S-adenosylhomocysteine in human plasma. Clinical Chemistry and Laboratory Medicine. 2016. Grade B. Measurement study examining liver-disease associations.
36. Kruglova MP, et al. The diagnostic and prognostic roles played by homocysteine, SAM, SAH, and their ratios in chronic kidney disease. International Journal of Molecular Sciences. 2023. Grade B. Review and human evidence on renal confounding.
Mechanistic and Translational Support
37. Martinez-Uña M, et al. S-adenosylmethionine increases circulating very-low-density lipoprotein clearance in non-alcoholic fatty liver disease. Journal of Hepatology. 2015. Grade B/C. Translational work linking hepatic SAM, PEMT, and lipid export.
38. Ye C, Sutter BM, Wang Y, Kuang Z, Tu BP. A metabolic function for phospholipid and histone methylation. Molecular Cell. 2017. Grade C. Experimental evidence connecting SAM availability with competing methylation demands.
39. Walker AK. 1-carbon cycle metabolites methylate their way to fatty liver. Trends in Endocrinology and Metabolism. 2017. Grade B/C. Integrative review of one-carbon metabolism and hepatic lipid accumulation.
40. Schalinske KL, Smazal AL. Homocysteine imbalance: a pathological metabolic marker. Advances in Nutrition. 2012. Grade B. Review of homocysteine, SAH, remethylation, and transsulfuration.
1. Mato JM, Martínez-Chantar ML, Lu SC. S-adenosylmethionine metabolism and liver disease. Annals of Hepatology. 2013. Grade B. Comprehensive mechanistic review integrating human liver disease and experimental evidence.
2. Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiological Reviews. 2012. Grade B. Authoritative review of MAT1A, MAT2A, GNMT, SAM homeostasis, liver injury, and carcinogenesis.
3. Ramani K, Lu SC. Methionine adenosyltransferases in liver health and diseases. Liver Research. 2017. Grade B. Review of methionine adenosyltransferase isoforms, the MAT1A/MAT2A switch, fibrosis, and cancer biology.
4. Li Z, Wang F, Liang B, Su Y, Sun S, Xia S, et al. Methionine metabolism in chronic liver diseases: an update on molecular mechanism and therapeutic implication. Signal Transduction and Targeted Therapy. 2020. Grade B. Detailed review of methionine-cycle remodeling across chronic liver diseases.
5. Frau M, Feo F, Pascale RM. Pleiotropic effects of methionine adenosyltransferases deregulation in liver cancer. International Journal of Molecular Sciences. 2013. Grade C. Mechanistic and translational evidence on methionine adenosyltransferase dysregulation in hepatocarcinogenesis.
6. Ji Y, Nordgren KK, Chai Y, Hebbring SJ, Jenkins GD, Abo RP, et al. Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and genotype-phenotype correlation. Drug Metabolism and Disposition. 2012. Grade B. Human genetic and functional study of MAT1A and GNMT variation.
Inherited Methylation Disorders
7. Barić I, Staufner C, Augoustides-Savvopoulou P, Chien YH, Dobbelaere D, Grünert SC, et al. Consensus recommendations for the diagnosis, treatment and follow-up of inherited methylation disorders. Journal of Inherited Metabolic Disease. 2017. Grade A. Formal consensus covering methionine adenosyltransferase I/III, GNMT, AHCY, and adenosine kinase deficiencies.
8. Chamberlin ME, Ubagai T, Mudd SH, Wilson WG, Leonard JV, Chou JY. Methionine adenosyltransferase I/III deficiency: novel mutations and clinical variations. American Journal of Human Genetics. 2000. Grade C. Human case series and molecular characterization.
9. Chien YH, Abdenur JE, Baronio F, Bannick AA, Corrales F, Couce M, et al. Mudd's disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotes. Orphanet Journal of Rare Diseases. 2015. Grade B/C. Multicenter rare-disease survey with genotype and phenotype data.
10. Barić I, Fumić K, Glenn B, Cuk M, Schulze A, Finkelstein JD, et al. S-adenosylhomocysteine hydrolase deficiency in a human: a genetic disorder of methionine metabolism. Proceedings of the National Academy of Sciences. 2004. Grade C. Foundational human case and biochemical characterization.
11. Buist NRM, Glenn B, Vugrek O, Wagner C, Stabler S, Allen RH, et al. S-adenosylhomocysteine hydrolase deficiency in a 26-year-old man. Journal of Inherited Metabolic Disease. 2006. Grade C. Adult case demonstrating long-term multisystem expression.
12. Huang Y, et al. The biochemical profile and dietary management in S-adenosylhomocysteine hydrolase deficiency. Molecular Genetics and Metabolism Reports. 2022. Grade C. Case report plus synthesis of reported biochemical patterns.
13. Almuhsen N, et al. Clinical utility of methionine restriction in adenosine kinase deficiency. JIMD Reports. 2021. Grade C. Case-based evidence on dietary management in a rare disorder.
14. Barić I, et al. Glycine N-methyltransferase deficiency: a member of the expanding family of inherited disorders of methylation. Molecular Genetics and Metabolism. 2016. Grade C. Rare-disease review and patient evidence.
Liver-Disease Guidance and Clinical Context
15. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023. Grade A. Standard clinical assessment, fibrosis risk stratification, and management guidance.
16. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease. Journal of Hepatology. 2024. Grade A. Current European MASLD guidance.
17. Tang Y, et al. Association of serum methionine metabolites with non-alcoholic fatty liver disease. Nutrition and Metabolism. 2022. Grade B. Human observational evidence for altered circulating SAM, SAH, and homocysteine in fatty liver.
18. Piras IS, et al. Hepatic PEMT expression decreases with increasing severity of NAFLD in obese individuals and postmenopausal women. International Journal of Molecular Sciences. 2022. Grade B. Human liver-tissue study linking PEMT expression with disease severity.
19. Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A, et al. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. American Journal of Clinical Nutrition. 2012. Grade B. Human cohort examining choline intake and histologic severity.
Choline, PEMT, and Controlled Human Evidence
20. da Costa KA, Kozyreva OG, Song J, Galanko JA, Fischer LM, Zeisel SH. Common genetic polymorphisms affect the human requirement for the nutrient choline. FASEB Journal. 2006. Grade A/B. Controlled human depletion-repletion study with genetic modifiers.
21. Sha W, da Costa KA, Fischer LM, Milburn MV, Lawton KA, Berger A, et al. Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline. FASEB Journal. 2010. Grade A/B. Controlled human feeding study with objective liver outcomes.
22. Mehedint MG, Zeisel SH. Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. Current Opinion in Clinical Nutrition and Metabolic Care. 2013. Grade B. Review centered on human depletion studies and hepatic mechanisms.
23. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Current Opinion in Gastroenterology. 2012. Grade B. Integrative review of choline, PEMT, very-low-density lipoprotein export, and fatty liver.
24. Li J, et al. Phosphatidylethanolamine N-methyltransferase: from functions to diseases. Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids. 2023. Grade B/C. Mechanistic review of PEMT and phosphatidylcholine biology.
25. Obeid R, et al. Choline: a scoping review for Nordic Nutrition Recommendations 2023. Food and Nutrition Research. 2023. Grade A/B. Evidence synthesis on choline requirements and health outcomes.
SAMe Intervention Evidence
26. Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Journal of Hepatology. 1999. Grade A/B. Long-term randomized trial with subgroup-dependent findings.
27. Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF, et al. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcoholism: Clinical and Experimental Research. 2011. Grade A. Randomized trial finding no added benefit over placebo during abstinence.
28. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database of Systematic Reviews. 2001. Grade A. Systematic review emphasizing limited and heterogeneous evidence.
29. Guo T, Chang L, Xiao Y, Liu Q. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS One. 2015. Grade A/B. Evidence synthesis across heterogeneous liver conditions.
30. Noureddin M, et al. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: a systematic review. World Journal of Hepatology. 2020. Grade A/B. Review of biochemical and symptom outcomes in cholestasis.
31. Baden KER, et al. S-Adenosylmethionine for liver health: a systematic review. Nutrients. 2024. Grade A/B. Recent systematic review, interpreted cautiously because included conditions and outcomes are heterogeneous.
Measurement and Interpretation
32. Adaikalakoteswari A, et al. Simultaneous detection of five one-carbon metabolites in plasma by liquid chromatography-tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine. 2016. Grade B. Analytical study of SAM, SAH, methionine, homocysteine, and methylmalonic acid measurement.
33. Bravo AC, et al. Method optimisation and profiling of S-adenosylmethionine and S-adenosylhomocysteine in healthy adults. Nutrients. 2022. Grade B. Methodological and reference-profile evidence.
34. Klepacki J, Brunner N, Schmitz V, Klawitter J, Christians U. Development and validation of an LC-MS/MS assay for the determination of SAM and SAH in human plasma. Journal of Chromatography B. 2013. Grade B. Analytical validation and discussion of clinical confounders.
35. Hao X, et al. Immunoassay of S-adenosylmethionine and S-adenosylhomocysteine in human plasma. Clinical Chemistry and Laboratory Medicine. 2016. Grade B. Measurement study examining liver-disease associations.
36. Kruglova MP, et al. The diagnostic and prognostic roles played by homocysteine, SAM, SAH, and their ratios in chronic kidney disease. International Journal of Molecular Sciences. 2023. Grade B. Review and human evidence on renal confounding.
Mechanistic and Translational Support
37. Martinez-Uña M, et al. S-adenosylmethionine increases circulating very-low-density lipoprotein clearance in non-alcoholic fatty liver disease. Journal of Hepatology. 2015. Grade B/C. Translational work linking hepatic SAM, PEMT, and lipid export.
38. Ye C, Sutter BM, Wang Y, Kuang Z, Tu BP. A metabolic function for phospholipid and histone methylation. Molecular Cell. 2017. Grade C. Experimental evidence connecting SAM availability with competing methylation demands.
39. Walker AK. 1-carbon cycle metabolites methylate their way to fatty liver. Trends in Endocrinology and Metabolism. 2017. Grade B/C. Integrative review of one-carbon metabolism and hepatic lipid accumulation.
40. Schalinske KL, Smazal AL. Homocysteine imbalance: a pathological metabolic marker. Advances in Nutrition. 2012. Grade B. Review of homocysteine, SAH, remethylation, and transsulfuration.
